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ABSTRACT 
To date the current available treatments are chemotherapy and surgery in cancer and only 
seldomly treatments or cures for human genetic diseases exist. Therefore scientists are 
seeking for new methods of therapy and many focus their research on stem cells and 
possible stem cell therapy as major advances were made in the recent years.  
On the one hand embryonic stem cells harbor the potential to differentiate into lineages of 
the three germ layers and are rapidly proliferating. However, besides the ethical concerns, 
they have the risk of teratoma formation in SCID mice. On the other hand adult stem cells 
derived from various tissues, have limited proliferation capacity and differentiation 
potential. In 2003 the discovery of stem cells in the human amniotic fluid (hAFS cells) 
smartened up the field of stem cell biology as these cells can differentiate into cells of the 
three germ layers, are highly proliferative and do not harbor the risk of teratoma 
formation. 
The mTOR pathway plays a critical role in cell growth, cell cycle regulation, translation, 
apoptosis, energy and nutrient sensing. Furthermore it is deregulated in many cancers and 
human genetic diseases. One major regulator of the mTOR pathway is TSC2, encoding 
tuberin, which forms a complex with TSC1 and mutation in either one gene causes 
tuberous sclerosis (TSC), a human genetic disease affecting 1:6000 births. In 2003 a 
novel negative regulator of mTORC1 was identified – the proline rich AKT substrate of 
40kDa (PRAS40), which was found to be deregulated in some cancers and has a possible 
role in diabetes. We proved that hAFS cells are able to form embryoid bodies and that this 
is dependent on mTOR. Secondly, we showed that these cells were capable of integrating 
and differentiating into renal structures. 
The major aim of this thesis was to study the role of the two major regulators of mTORC1 
– TSC2 and PRAS40 – in development using hAFS cells derived embryoid bodies to 
recapitulate early embryonic development. Knockdown of PRAS40 and TSC2 led to 
increased apoptosis in embryoid bodies, which could not be rescued by the mTORC1 
inhibitor rapamycin; however it was possible to revert this effect by knocking down 
mTOR. This led us to the conclusion that a) PRAS40 and TSC2 are major anti-apoptotic 
gatekeepers in early development and b) this regulation depends on rapamycin- 
insensitive functions of mTOR. 
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ZUSAMMENFASSUNG 
Zurzeit sind chemotherapeutische oder operative Therapie bei Krebs die häufigsten 
Behandlungsarten und nur selten existieren Therapien für humangenetische Erkrankungen. 
Deshalb suchen Wissenschafter nach neuen Methoden und legen dabei ihr Augenmerk auf die 
Stammzellforschung, welche  in den letzten Jahren wesentliche Fortschritte gemacht hat. 
 Embryonale Stammzellen besitzen einerseits das Potential in alle drei Keimblätter zu 
differenzieren und haben eine hohe Proliferationsrate. Neben den ethischen Bedenken besteht 
auch noch das Risiko einer Tumorentstehung. Andererseits existieren adulte Stammzellen aus 
den unterschiedlichsten Geweben, welche aber nur begrenzte Proliferationsrate und 
Differenzierungspotential besitzen. Mit der Entdeckung von Stammzellen in humanem 
Fruchtwasser im Jahre 2003 wurde frischer Wind in das Gebiet rund um die 
Stammzellforschung gebracht, da diese Zellen in viele Zellarten der drei Keimblätter 
differenzieren können, hohe Proliferationsraten haben und keine Teratome formen. 
Der mTOR Signalweg spielt eine wichtige Rolle bei Zellwachstum, Zellzyklusregulation, 
Translation, Apoptose, Energie- und Nährstoffhaushalt. Darüber hinaus ist dieser in vielen 
Krebsarten und genetischen Erkrankungen dereguliert. Ein wesentlicher Regulator des mTOR 
Signalwegs ist TSC2, das gemeinsam mit TSC1 einen Komplex bildet. Eine Mutation in 
einem der beiden Gene löst Tuberöse Hirnsklerose aus, eine humangenetische Erkrankung, 
die 1 von 6000 Geburten betrifft. Im Jahre 2003 wurde ein weiterer Regulator von mTORC1 
identifiziert – PRAS40, welcher in manchen Krebserkrankungen dereguliert ist und eine 
mögliche Rolle bei Diabetes spielt. Wir konnten beweisen, dass es möglich ist, embryoid 
bodies aus Fruchtwasserstammzellen zu formieren und dass dieser Vorgang mTOR-abhängig 
ist. Zweitens dazu imstande sind sich in renale Strukturen zu integrieren und dort zu 
differenzieren. 
Das Ziel dieses Projekts war es, die Rolle der zwei wichtigsten Regulatoren von mTORC1 – 
PRAS40 und TSC2 – in der früher embryonalen Entwicklung, anhand von embryoid bodies 
aus humanen Fruchtwasserstammzellen, zu studieren. Der Knockdown von PRAS40 und 
TSC2 löste massive Apoptose aus, welche durch den chemischen mTOR Inhibitor 
Rapamycin nicht verhindert werden konnte. Allerdings konnte diese aber durch den 
Knockdown von mTOR revertiert werden. Dies brachte uns zur Erkenntnis dass a) PRAS40 
und TSC2 wesentliche anti-apoptotische Schlüsselmoleküle in der frühen embryonalen 
Entwicklung sind und b) diese Regulation von Rapamycin-insensitiven Funktionen mTORs 
abhängt. 
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1. INTRODUCTION 
Medicine and science are definitely one of the fastest growing disciplines in the world 
and have substantially enriched the quality of life and life span of men. However, heart 
disease, cancer and a number of severe human genetic diseases still cannot be cured. 
Therefore scientists all over the world are searching for new ways of therapy and cures. 
For most cancer patients the only possible therapy is surgery or chemotherapy, which 
often only help partially. Scientists trade embryonic stem cells as the new potent tool to 
cure a number of diseases. However, although embryonic stem cells are such a potent 
source and could be used in many different applications, they do bare some difficulties 
and problems still to overcome e.g. teratoma formation in SCID mice. The past years, a 
new source of stem cells was found in the amniotic fluid, the so called amniotic fluid stem 
cells; and these are a new promising tool, which do not raise ethical issues like embryonic 
stem cells do. 
An important regulator of the insulin signaling pathway is the mTOR complex 1 
(mTORC1), which is deregulated in many cancers as some very prominent oncogenes 
and/or tumor suppressors are upstream of mTORC1 e.g. PTEN, LKB1, AMPK, ERK and 
its direct upstream regulator TSC2, a tumor suppressor (Rosner et al., 2008a). The tumor 
suppressor TSC2, encoding tuberin, forms a heterodimer with TSC1, encoding harmatin, 
and mutations in either gene leads to tuberous sclerosis (TSC) affecting 1:6000 births 
(Rosner et al., 2008b).  
This thesis combines the potential of human amniotic fluid stem cells with the 
identification of the regulation of the mTORC1 regulators PRAS40 and TSC2 in an in 
vitro embryonic developmental system.  
 
1.1 Stem cells 
Since the discovery and isolation of stem cells new revolutionary medical appliances and 
therapeutics are expected. This new research field has revolutionized developmental 
genetics and biology, as one can study in vitro differentiation of stem cells into all kinds 
of cells from the three germ layers or in vitro development and their future use in 
regenerative medicine. 
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1.1.1 Characteristics of stem cells 
Stem cells are usually defined to have special characteristics e.g. pluripotency and self 
renewal. Self-renewal is the ability to go through numerous cell divisions while 
maintaining an undifferentiated state e.g. asymmetric cell division into an undifferentiated 
mother cell and a differentiated daughter cell. Pluripotency, on the other hand, is the 
potential to differentiate into any cell type of the three germ layers. Currently a list of 
general criteria to evaluate the developmental differentiation potential of cells was 
provided by Jaenisch and Young in 2008, which include: in vitro tri-lineage 
differentiation like embryoid bodies (EBs), in vivo teratoma formation, postnatal chimera, 
germline contribution, and tetraploid complementation (Jaenisch and Young, 2008).  
1.1.2 Embryonic stem cells 
As their name suggests, these cells are derived from the inner cell mass (ICM) of the pre-
implantation embryo (Odorico et al., 2001). The research field on embryonic stem (ES) 
cells evolved in the 1950s with the study of teratocarcinoma cells. Then the first mouse 
embryonic stem cell lines were generated. In 1998 Thomson et al. were the first ones who 
cultured and expanded human embryonic stem (hES) cells (Evans and Kaufman, 1981; 
Martin, 1981; Thomson et al., 1998). To maintain their undifferentiated state ES cells 
express various transcription factors that suppress differentiation and favor pluripotency 
such as Oct-4, Nanog, Sox-2 (Fong et al., 2008; Mitsui et al., 2003; Pesce and Scholer, 
2001). To date most of the attention is drawn to degenerative diseases such as Parkinson’s 
disease, multiple sclerosis or spinal chord injury to be cured through stem cell therapy. 
On the one hand ES cells raise hope for new and potential therapies to cure severe 
diseases like cancer or inherited diseases; on the other hand this field is accompanied with 
ethical concerns, as the generation of ES cells means destroying an embryo. 
1.1.3 Induced pluripotent stem cells 
This new type of stem cells was first generated in 2006 by Takahashi and Yamanaka and 
overcomes the ethical concerns of ES cells, as for their generation not a single embryo is 
needed. Induced pluripotent stem (iPS) cells are pluripotent stem cells developed from a 
somatic cell. The cell is forced to express certain key genes, namely Oct 3/4 (POU5F1), 
the transcription factor Sox2, the proto-oncogene c-Myc and Klf4 (Krueppl-like factor 4) 
to sufficiently reprogram adult cells to cells closely resembling ES cells (Takahashi and 
Yamanaka, 2006). Modifying the reintroduced sequences by reactivation of Oct-4 or 
Nanog promoter resulted in even better iPS cells more closely resembling ES cells and 
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were even able to contribute to the germline (Wernig et al., 2007). However, dispite very 
similar behavior, iPS cells still had a much higher incidence of tumor formation 
presumably due to the expression of c-Myc (Ben-David and Benvenisty, 2011; Maherali 
et al., 2007). Just recently the Jaenisch group provided an elegant way to generate human 
iPS cells free from reprogramming factors via Cre-recombinase excisable lentiviruses. 
The cells maintain a gene expression profile more similar to hES cells and can be 
differentiated into specific tissue (Soldner et al., 2009). It was assumed until recently that 
iPS cells behave like their embryonic counterparts regarding tumorigenicity. However, 
evidence is accumulating that suggests that there are important genomic and epigenetic 
differences between them influencing their tumorigenicity (Ben-David and Benvenisty, 
2011). 
1.1.4 Fetal stem cells 
1.1.4.1 The function of the amnion and amniotic fluid 
The amnion is a membrane surrounding and protecting the embryo during development 
and pregnancy (Dobreva et al., 2010). Between the fourth and the fifth week of pregnancy 
the amniotic fluid (liquor amnii) starts to accumulate within the amnion. It increases in 
volume until approximately the 6th to 7th month of pregnancy, at the end women usually 
carry about 1 liter of amniotic fluid. The amniotic fluid allows movements of the embryo 
and functions as a preventing shock absorber that protects against ascending infections, 
traumas and toxins (Calvin and Oyen, 2007). It contains solids, urea and other extractives 
from the embryo, protein and sugar. The amniotic membrane has another important task 
as it suppresses the semiallogenic immune response against the fetus (Bryant-Greenwood, 
1998; Calvin and Oyen, 2007). 
1.1.4.2 Amniotic fluid cells 
Originally, since the 1970s, human amniotic fluid was used to examine the fetus for 
human genetic diseases through routine prenatal diagnostics. Usually, non invasive 
techniques such as ultrasound are done routinely in all pregnancies. If these show 
abnormalities, or if there is a predisposition of genetic diseases in the family or it is a 
high-risk pregnancy due to the age of the mother, invasive methods are suggested. There 
are several possibilities: chorionic villus biopsy, which can be performed from the 10th 
week of gestation, cordocentesis from the 20th week and thirdly amniocentesis, starting 
around the 15th week. Amniotic fluid as mentioned above slowly starts to build up and 
reaches its maximum amount in the last trimester of gestation. As soon as the fetus starts 
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to swallow and subsequently “breathing”, pulmonary, tracheal, nasal and oral particles 
add up to amniotic fluid (Underwood et al., 2005).  
Although culturing of amniotic fluid (AF) cells was broadly established, nothing was 
really known about these cells and their properties (Prusa and Hengstschlager, 2002). It 
was only in 2001 that a group tried to engineer tissue constructs from cells found in the 
amniotic fluid. Immunocytochemical analysis of the AF cells showed a mesenchymal and 
fibroblast like cell lineage. These cells also proliferated significantly faster than 
comparable fetal and adult cells (Kaviani et al., 2001). The first time expression of Oct-4, 
a pluripotency marker for stem cells, was found in some cells of the amniotic fluid by our 
laboratory (Karlmark et al., 2005; Prusa et al., 2003). The expression of Oct-4 was proven 
by immunocytochemistry, RT-PCR and Western blotting, and therefore it was suggested 
that amniotic fluid is a source of pluripotent stem cells. AF cell population is 
heterogeneous, exhibits various cells in various differentiation stages and from all three 
germ layers. They either derive from the embryo or the amniotic membrane. Cells derived 
from earlier gestational stages have a higher expression of endo- and mesodermal markers 
compared to cells derived from later stages (Perin et al., 2008).  
1.1.4.3 Human amniotic fluid stem cells 
After it was clear that the human amniotic fluid contains some cells, which express the 
pluripotency marker Oct-4, several groups started to isolate human amniotic fluid stem 
cells (hAFS cells) using various protocols (De Coppi et al., 2007; Tsai et al., 2004). All of 
the isolated cells show overlapping marker expression e.g. Oct-4, CD34, CD44, CD45, 
CD105 and HLA-ABC and they might all be offspring of the same cell type (Siegel et al., 
2008). HAFS cells do belong to the class of fetal stem cells (Figure 1.1.1). 
 
Figure 1.1.1  Model for the differentiation potential of the different stem cell types 
compared to each other. The fetal stem cells are thought to be a new class of stem cells whose 
developmental state is somewhere between the embryonic stem cells and the adult stem cells 
(Pappa and Anagnou, 2009). 
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It was in 2007 that DeCoppi et al. provided a new isolation protocol for stem cells found 
in the amniotic fluid. This protocol is based on the fact that 1% of the cells in cultures of 
human amniotic fluid express the surface marker c-Kit (CD117), the receptor for stem 
cell factor (De Coppi et al., 2007). C-Kit positive cells were separated from the other cells 
by magnetic bead cell sorting and established monoclonal cell lines via minimal dilution. 
Cells do have a typical doubling time of 36h. They exhibit a normal karyotype and retain 
long telomeres, and after even 250 population doublings they showed a homogeneous and 
diploid DNA content in the G1 phase of the cell cycle. Another important factor is that 
these cells do not show teratocarcinoma growth in SCID mice. These hAFS cells could be 
cultivated and differentiated into lineages of all three germ layers, such as osteogenic, 
myogenic, adipogenic, endothelial, hepatic and neurogenic lineage (De Coppi et al., 2007; 
Kolambkar et al., 2007; Perin et al., 2008). These findings strongly support these cells to 
be pluri- or at least multipotent, which has been accounted solely to ES cells then (Figure 
1.1.1). The high potential of hAFS cells was not only shown through differentiation 
protocols of these cells. Various groups were able to show that hAFS cells could integrate 
into murine embryonic kidneys (E 12.5 – 18) or murine embryonic kidney rudiments (E 
11.5) in vitro and differentiate into de novo kidney structures e.g. renal vesicle, C- and S-
shaped bodies, ureteric bud (Perin et al., 2007; Siegel et al., 2010). Another important 
finding was that hAFS cells can form EBs, an in vitro 3D model system that mimics 
embryonic development in the very early stages of development and differentiation (Valli 
et al., 2010) and that EB formation is dependent on mTOR. 
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1.2 Embryoid bodies (EBs) 
The study on EBs represents a unique tool to investigate the very early process of 
embryonic development. EBs are mimicking stages of pregastrulation development and 
early gastrulation and therefore are a good tool for scientists to study embryonic 
development in vitro and to search for new cures. 
1.2.1 The genesis of embryoid bodies 
EBs were first described in the 19th century by the Germans van Waldeyer-Hartz and 
Pfannenstiel as in vivo phenomena of ovarian tumors. The term “embryoid body” was 
given by the French Albert Peyron, describing them in testicular tumors (Weitzer, 2006). 
Arnold Levine generated EBs from teratoma cells in 1974 (Levine et al., 1974), being 
immediately followed by Gail Martin and J.F. Nicolas in 1975, who generated them from 
teratocarcinoma cells (Evans, 1981; Martin and Evans, 1975; Nicolas et al., 1975; 
Weitzer, 2006). Finally in 1981 EBs derived from ES cells, isolated from the inner cell 
mass of murine blastocysts, were generated (Evans and Kaufman, 1981; Martin, 1981). 
Since then numerous data has been published providing evidence that EBs represent an in 
vitro model for eutherian embryonic development and that the derived somatic cells may 
be used for cell therapy. It also became evident that EBs represent a good tool to study 
homozygous null alleles (Robertson et al., 1992) with subtle phenotypes that were either 
hidden in vivo (Bagutti et al., 1996; Milner et al., 1996; Weitzer, 2006) or caused early 
embryonic lethality (Di Cristofano et al., 1998; Fassler et al., 1995; Rohwedel et al., 
1998). However, only after the isolation of hES cells (Thomson et al., 1998), there was a 
boost in the EB research field. EBs derived from hES cells were shown to have a similar 
potential to that of murine EBs (Itskovitz-Eldor et al., 2000; Schuldiner et al., 2000).  
1.2.2 Embryonic stem cell influence on embryoid bodies 
One of the major problems that have to be considered in the ES cells and EB research 
field is that the ES cells isolated from the inner cell mass of a blastocyst are never from 
the same origin. Even if isolated at the same time point and from the same mouse strain, 
ES cells would behave differently. Self-renewal capacity, plasticity and differentiation 
control, are therefore highly variable among even isogenic ES cell lines generated in 
different laboratories. EB development is not only influenced by the genetic background 
but also by the culture conditions. Additional parameters that influence ES cell potential 
and EB differentiation include the developmental stage of the embryo when ES cells were 
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generated, time to reach confluency in vitro, the source and batch of fetal calf serum and 
at last the handling of the cells by the investigator (Weitzer, 2006). The initial number of 
stem cells for example determines the number of ES cells which aggregate to form EB, 
and the final number of cells in the compact EB strongly influences further development 
of the cells (Bader et al., 2001; Dang et al., 2004). 
1.2.3 Pregastrulation-like development of embryoid bodies 
The first cell lineage emerging from the compacted morula is the trophectoderm, which 
contributes to the placenta (Tanaka et al., 1998). The inner cell mass is then giving rise to 
the primitive endoderm or the hypoblast (Watson and Barcroft, 2001) and the remaining 
primitive ectoderm constitutes the epiblast. During implantation, primitive endoderm 
differentiates into two extraembryonic lineages, the visceral and the parietal endoderm, 
which both form the yolk sac (Gardner, 1985).   
The study of embryonic-like developmental processes in an EB requires size uniformity. 
This can be achieved through the hanging drop method or suspension culture in 96-Well-
Plates. These cultures guarantee the formation of EBs uniform in size and with an equal 
initial number of ES cells. A critical mass of cells within EBs is essential for development 
and achieved through a sufficient number of aggregating ES cells. Once an EB has 
formed, the cell mass fundamentally influences further development of EBs (Bader et al., 
2001; Miki, 1999; Nicolas et al., 1975). In hanging drop cultures, mES cells aggregate 
within 24h and form an early morula-like structure. The initial number of ES cells must 
be significantly higher than the 16-64 cells of a morula to guarantee the development of 
all three germ layers in an EB later on (Bader et al., 2001; Dang et al., 2004). Usually, the 
initial number to form EBs ranges from 300-700 cells. Once ES cells have successfully 
aggregated and formed small spheres of roughly 50-100µm in diameter, by the 2nd day of 
in vitro development the irregular surface smoothens to morphologically resemble the 
morula compaction process (Weitzer, 2006). After 3 days EBs can reach a diameter of up 
to 200µm and the first primitive endoderm cells appear as refractive bubbles on the 
surface of the EB (Adamson et al., 1985; Grover et al., 1983). The outermost cells of EBs 
then start to express alphafetoprotein (αFP) (Miki, 1999) and N-acetyl-galactosamine 
epitopes (Bader et al., 2001). They continue to emerge until the entire surface of the 
sphere is covered by primitive endoderm by day 4 to 5 (Li et al., 2003; Smyth et al., 
1999). 
13 
 
These cells start to secrete components of the extracellular matrix to form a basement 
membrane (Aumailley et al., 2000; Gao et al., 2004; Murray and Edgar, 2001; Smyth et 
al., 1999), which effectively isolates the remaining ES cells from at least some 
environmental influences and consequently generates a new microenvironment for the 
emerging primitive ectoderm. Some ES cells develop into primitive ectoderm that 
reorganizes into a columnar epithelium surrounding a central cavity (Ikeda et al., 1999; 
Smyth et al., 1999). These cysts can either be expanded by apoptosis or the reorganization 
of the growing EB (Miki, 1999). Summing up EB development perfectly recapitulates the 
development of the hypoblast by producing primitive endoderm, which in turn gives rise 
to visceral and parietal endoderm; the latter then undergoes an epithelial to mesenchymal 
transition to mature mesenchymal parietal endoderm; therefore EBs provide the 
foundation for consecutive gastrulation-like development (Weitzer, 2006). 
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1.3 Cell death 
Cell death is a fundamental feature of an organism also being essential in embryonic 
development. It prevents auto-immune response, is essential for tissue homeostasis and 
DNA damaged cells undergo apoptosis. As true for numerous biological processes there 
is not only one single mechanism of cell death, there are several different ones ensuring 
the steady state or which are specialized to work under special conditions or in specific 
cell types. To date the following mechanisms of cell death are known: apoptosis – the 
programmed cell death, autophagy and necrosis. 
1.3.1 Apoptosis – programmed cell death 
Programmed cell death (Lockshin and Williams, 1965) – called apoptosis – is a regulated 
from of cellular suicide that is thightly controlled by a genetic program (Yuan and 
Horvitz, 2004). It is associated with certain characteristic morphological and biochemical 
manifestations such as membrane blebbing, cell shrinkage, chromatin condensation 
(Figure 1.3.1) and fragmentation of genomic DNA (Bursch et al., 1990; Kerr et al., 1972). 
After cell blebbing the apoptotic cell breaks into small, membrane-wrapped vesicles, 
termed “apoptotic bodies”, which are uptaken by macrophages or neighboring cells. 
Therefore any inflammatory responses are suppressed in vivo.  
 
Figure 1.3.1 Scheme of the different stages of apoptosis and its morphological 
manifestation. Apoptosis is starting first with nuclear condensation, followed by nuclear 
fragmentation, apoptotic body formation and at last phagocytosis (Figure adapted from 
http://en.wikipedia.org/wiki/File:Apoptosis.png). 
 
Apoptosis can be activated by two different pathways namely the extrinsic and the 
intrinsic apoptotic pathway. The extrinsic pathway is mediated by death receptors on the 
cell surface (Figure 1.3.2). Death receptors are members of the tumor-necrosis factor 
(TNF) family and are characterized by an intracellular death domain (Krammer, 1999; 
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Schmitz et al., 2000). When ligands bind to the respective death receptors, the death 
domains attract the intracellular adaptor protein FADD (Fas-associated death domain 
protein), which recruits the inactive forms of the caspase protease family. The initiator 
caspases, caspase-8 and caspase-10, are then recruited to the death-inducing-signalling 
complex (DISC). At the DISC complex the caspases are cleaved to activate the 
executioner/effector caspases e.g. caspase-3 (Danial and Korsmeyer, 2004; Igney and 
Krammer, 2002) or caspase-8 cleaved BID to turn on the mitochondrial pathway.  
 
Figure 1.3.2 Extrinsic or death receptor pathway. Binding to death ligands to their receptor 
leads to the formation of the DISC. In the DISC, the initiator procaspase-8 is recruited by FADD 
and is activated by autocatalytic cleavage (Igney and Krammer, 2002). 
 
The intrinsic or mitochondrial pathway is initiated via an apoptotic stimulus which 
affects the mitochondrial membrane. Mitochondria are organelles, existing in most 
eukaryotic cells, serving as energy suppliers as they produce most of the ATP needed by a 
cell. They have two very well defined compartments the matrix being surrounded by the 
inner membrane, and the intermembrane space surrounded by the outer membrane. The 
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membrane integrity undergoes severe changes during apoptosis concerning both 
membranes, leading to the dissipation of the inner transmembrane potential (∆ᴪm) and the 
release of  cytochrome c and other factors from the intramembraneous space (Liu et al., 
1996). The released cytochrome c forms a complex with APAF1 (apoptotic protease 
activating factor-1), ATP and pro-caspase-9 (Li et al., 1997) in the cytosol (Figure 1.3.3); 
in this complex, known as the apoptosome, caspase-9 is then activated through 
proteolysis (Martinou and Green, 2001; Zamzami and Kroemer, 2001), then processes 
and therefore activates caspase-3, caspase-6 or caspase-7. The active effector caspases 
cleave each other and start amplifying the proteolytic cascade of caspase activation (Igney 
and Krammer, 2002; Rathmell and Thompson, 1999).  
 
Figure 1.3.3 Intrinsic or mitochondrial death pathway. Proapoptotic BCL2 family proteins 
are important mediators of these signals. Activation of mitochondria leads to the release of 
cytochrome c into the cytosol, where it binds to APAF1 to form the apoptosome. There initiator 
caspase-9 is activated. This apoptotic pathway can be inhibited by anti-apoptotic proteins e.g. 
BCL-2 and BCL-XL and secondly via survival signals from the PI3K pathway (Igney and 
Krammer, 2002). 
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Within apoptosis there are two different types the caspase dependent apoptosis and 
caspase-independent apoptosis. Caspases do cleave their targets like nuclear lamins or 
CAD (caspase-activated deoxyribonuclease), which generates 180bp DNA fragments, 
after aspartic acid residues and catalyze a highly selective pattern of protein degradation. 
Besides, organelles remain morphologically intact – only subtle changes e.g. membrane 
permeabilization or protein degradation appear, whereas cell shrinkage and a reduced 
intracellular potassium level occur (Cohen, 1991; Thompson, 1995). As the remaining 
material is present in relatively small units, the apoptotic cell is readily phagocytosed by 
neighboring cells (Huettenbrenner et al., 2003) or engulfed by phagocytes, as they 
recognize an “eat me” signal, e.g. in mammals phosphatidylserine (PS), on the plasma 
membrane of a dying cell (Danial and Korsmeyer, 2004; Savill and Fadok, 2000). 
Caspase-independent apoptosis in mammalian cells has been attributed to two 
mitochondrial proteins endonuclease G and apoptosis-inducing factor (AIF) that 
translocate to the nucleus upon release (Li et al., 1997; Susin et al., 1999). AIF activates a 
nuclear DNAse (Kroemer and Reed, 2000), which cuts genomic DNA into 50kb 
fragments giving rise to a distinct nucleo-morphological phenotype of chromatin 
condensation (Susin et al., 2000). The nuclear translocation of AIF is dependent on poly 
(ADP-ribose) polymerase-1 (PARP-1). It attaches poly ADP-ribose to nuclear proteins 
such as histones and its activation leads to apoptosis under several conditions (Yu et al., 
2002). Vice versa proapoptotic activity of PARP-1 requires AIF function. Apoptosis 
during embryoid body cavitation for example is dependent on AIF (Joza et al., 2001).  
 
1.3.2 Necrosis 
Necrosis is an accidental form of cell death resulting from various stresses, such as 
physiochemical injury (temperature, radiation, radicals, toxic trauma), osmotic imbalance, 
energy deprivation. It is always the outcome of severe acute insults that cause almost 
instantaneously membrane depolarization and its disruption and cellular swelling 
(Huettenbrenner et al., 2003; Kerr et al., 1972). The spillage of cellular components 
induces inflammatory reactions affecting neighboring cells. Studies on excitotoxic 
neuronal deaths revealed an hyperactivation of NMDA channels and subsequently 
increases in intracellular Ca2+ and Ca2+ -dependent pathways through necrosis (Nicotera 
et al., 1997). Necrosis is an energy independent process, whereas apoptosis is strictly 
dependent on it; considering this ATP is the switch between apoptosis and necrosis. For 
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that reason energy depletion leads to necrosis (Eguchi et al., 1997; Grusch et al., 2002; 
Leist et al., 1997). Table 1.3.1 gives a summarized comparison of apoptosis and necrosis.  
 Table 1.3.1 Comparison between apoptosis and necrosis 
 
 
1.3.3 Autophagy 
This type of cell death has been implicated for the disposal of intracellular organelles and 
cytoplasmic material, where lysosomes are involved. These lysosomes assemble and are 
sequestered within double membrane and are known as autophagosomes. Consumption of 
these vesicles is divided into four distinct steps: induction and cargo packaging, formation 
and completion, docking and fusion, and breakdown (Danial and Korsmeyer, 2004). The 
Apoptosis Necrosis
physiological or pathological always pathological
single cells sheets of cells
energy dependent energy independent
cell shrinkage cell swelling
membrane integrity maintained membrane integrity lost
role for mitochondria and cytochrome c no role for mitochondria
no leak of lysosomal enzymes leak of lysosomal enzymes
characteristic nuclear changes nuclei lost
apoptotic bodies from no apoptotic bodies
DNA cleavage no DNA cleavage
activation of specific proteases no protease activation
tightly regulated process not regulated
evolutionary conserved not conserved
dead cells ingested by neighbouring cells
dead cells ingested by neutrophils and 
macrophages
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autophagosomes further integrate with lysosomes and build up the autophagic vacuoles. 
Despite a few mitochondria, required for ATP production, the others are degraded. In 
contrast to apoptosis the cytoskeleton remains intact (Bursch, 2001). Some reports also 
state that autophagy is a caspase-independent process (Huettenbrenner et al., 2003; 
Kitanaka and Kuchino, 1999; Quignon et al., 1998). In mammals the autophagy inducing 
gene is beclin1 (Liang et al., 1999), a Bcl-2 interacting protein. It links autophagy to the 
PI3-kinase and mTOR pathways as they can influence shared intermediates, such as 
p70S6K and mTOR (Danial and Korsmeyer, 2004).  
 
1.3.4 Regulation of apoptosis during development 
The development of an embryo is characterized by the means of a high proliferation rate 
and differentiation of cells. Hand in hand with them, starting at eight-cell stage, the rate of 
apoptosis increases, as it is known that development and morphogenesis is not only 
regulated by proliferation and differentiation but also through apoptosis e.g. development 
of the hand. In the embryo chromosomal abnormalities or suboptimal environmental 
conditions for example can result in poor embryo development or cell death (Jacobson et 
al., 1997; Wells et al., 2005; Yuan and Kroemer). These abnormal cells have to be 
eliminated, due to the fact that the high frequency of cell division could lead to a large 
number of these cells and would probably lead to an underdeveloped or sick offspring. 
During late stage apoptosis, when apoptotic bodies have formed, they are either 
phagocytosed by neighboring cells, dispersed into the blastocyst cavity or perivitelline 
space in the embryo (Hardy, 1999).  
During development of the preimplantation embryo, misplaced, falsely determined, or 
unneeded cells have to be eliminated. Additionally apoptosis is extremely important for 
development, such as formation of the amniotic cavity, and control of the cell number of 
developing organs. Erythrocytes and thrombocytes are also produced by the means of the 
apoptotic cascade (Jacobson et al., 1997). The Fas system, being one of the key regulators 
of apoptosis, is expressed from the four-cell stage onward in human embryos (Kawamura 
et al., 2001). Furthermore, factors which are teratogenic, such as retinoic acid, are able to 
reduce inner cell mass numbers by inducing apoptosis (Huang et al., 2005; Huang et al., 
2003). TNFα is produced by the embryo itself and acts via EGF-R, the survival factor 
IGF-Ι is mainly of maternal origin (Hardy and Spanos, 2002). Good key markers for 
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impaired embryo growth appear to be altered ratios of e.g Bcl-xL:Bak and Bcl2:Bax in 
favor for Bak and Bax, respectively, leading to apoptotic elimination of altered cells 
(Jeong et al., 2004; Yuan and Kroemer). A decrease in gene expression between 
fertilization and the onset of the embryonic genome has also been demonstrated for genes 
involved in apoptosis, such as the Bcl-2 family (Metcalfe et al., 2004). Other pro-
apoptotic genes like RB1 and Bad reach their maximum transcription levels only after 
compaction, when the first apoptotic signs are observed (Spanos et al., 2002; Wells et al., 
2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
21 
 
1.4 The mammalian target of rapamycin (mTOR) 
The mammalian target of rapamycin (mTOR) pathway is one of the major regulators in 
protein synthesis and cell growth. The mTOR pathway is activated in response to 
nutrients (amino acids), growth factors (insulin) and cellular energy (ATP) (Sarbassov et 
al., 2005a; Wullschleger et al., 2006). The history of mTOR began with the discovery of 
the anti-fungal macrolide rapamycin in the 1970s, produced by the bacterial strain 
Streptomyces hygroscopicus. The name rapamycin derives from the place it was found, 
namely on the Easter Island “Rapa Nui”. Initially rapamycin was used as an anti-fungal 
agent; however, by further investigating this molecule, it was found that it is an effective 
immunosuppressor used after organ transplantation or chemotherapy. Just lately 
rapamycin was tested as an anti-cancer therapeutic (Chueh and Kahan, 2005; Di Mario et 
al., 2004; Vezina et al., 1975; Yang and Guan, 2007). Through rapamycin a protein was 
found that would bind to it – the target of rapamycin (TOR).  
1.4.1 Structure and genetics of mTOR 
The TOR protein itself is approximately 280kDa, containing several structural and 
functional domains. In the amino-terminal half a number of HEAT repeats can be found 
that are important for protein interactions. The FRB domain, located in the middle of the 
protein, is the binding domain for the FKBP12-rapamycin complex, which inhibits mTOR 
activity (Brown et al., 1994; Jayaraman and Marks, 1993). The catalytic unit of mTOR is 
located in the C-terminal region. Its kinase domain places TOR to the family of 
phosphatidylinositol kinase-related kinases (PIKK). Typical for the PIKK family are so-
called FAT and FATC domains (Figure 1.4.1). Overall the TOR protein is very well 
conserved from yeast to mammals (Hall, 2008).  
The mTOR protein is found in two structurally and functionally distinct complexes: 
mammalian target of rapamycin complex 1 (mTORC1) and mammalian target of 
rapamycin complex 2 (mTORC2). In 1994, the first interacting proteins of this complex 
were discovered (Brown et al., 1994; Chiu et al., 1994; Sabatini et al., 1994). Much later 
mTORC2 was found to exist with different proteins associated (Loewith et al., 2002). 
mTORC1 consists of mTOR, its scaffold protein raptor, mLST8 and is highly sensitive to 
rapamycin. Newer publications additionally add PRAS40 to mTORC1 and also DEPTOR 
(Dunlop and Tee, 2009; Ma and Blenis, 2009; Meric-Bernstam and Gonzalez-Angulo, 
2009; Peterson et al., 2009). The mTORC2 shares mTOR and mLST8 protein with 
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mTORC1, but has two other proteins necessary to form that complex – rictor and sin1. 
Sometimes protor and DEPTOR are also added to the complex. For a long time it was 
thought that mTORC2 is insensitive to rapamycin, however after a 24h exposure of 
rapamycin the activity of mTORC2 is diminished (Sarbassov et al., 2006). The 
dissociation of mTORC2 by rapamycin is achieved through the dephosphorylation of 
rictor and sin1 (Rosner and Hengstschlager, 2008). 
 
Figure 1.4.1 Structure and complexes of mTOR a) Domain structure of mTOR. N-terminal 
region is composed of tandem HEAT repeats and C-terminal half contains FAT domain, followed 
by FRB domain, a kinase domain and the FATC domain. b) Shows composition of mTORC1 and 
mTORC2, how these two complexes are stimulated and their downstream effects / function (Ma 
and Blenis, 2009). 
 
In contrast to mTORC1 the function of mTORC2 seems to be independent of growth 
factors (Facchinetti et al., 2008) and its function is evolutionary conserved. mTORC2 
mainly controls cytoskeleton dynamics, metabolism, proliferation, whole body growth 
and survival (Cybulski et al., 2009; Jacinto et al., 2004; Loewith et al., 2002; Sarbassov et 
al., 2004). 
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The PI3K-AKT-mTOR pathway is activated by growth factors or insulin, which bind to 
the corresponding tyrosine receptor kinases. This leads to an intracellular phosphorylation 
event and type Ia phosphoinositide 3-kinases (PI3K) are recruited to the plasma 
membrane. In the next step PI3K phosphorylates membrane phosphoinositides at the 3’ 
position to generate PI(3,4,5)P3 and related lipids, which lead to recruitment of the 
serine/threonine kinase AKT to the membrane through its PH domain. To be fully 
activated AKT is then phosphorylated at S473 by mTOR complex 2 (mTORC2) and other 
kinases, and at T308 by PDK1 (Alessi et al., 1997; Sarbassov et al., 2005b; 
Vanhaesebroeck and Alessi, 2000). Active AKT phoshorylates TSC2 on S939 and T1462, 
as well as PRAS40 on T246, which blocks their inhibitory function towards mTORC1. 
Besides the PI3K pathway, tuberin and therefore mTORC1 are also regulated by Rsk, 
Erk, AMPK and GSK3ß (Dan et al., 2002; Roux et al., 2004; Soulard and Hall, 2007). 
 
Figure 1.4.2 mTORC1 regulation via AKT-PRAS40 and AKT-TSC. 
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If tuberin is phosphorylated by AKT, Rsk or Erk for example it cannot execute its 
GTPase function towards Rheb. In course of this Rheb, in its active state, subsequently 
binds to mTORC1 and activates the complex (Avruch et al., 2006; Hall, 2008; Rosner et 
al., 2006). With the discovery of PRAS40, a second and more direct inhibitor of 
mTORC1 was found, also being regulated through phosphorylation by AKT, subsequent 
14-3-3 binding and removal of the complex (Kovacina et al., 2003; Sancak et al., 2007; 
Vander Haar et al., 2007), giving AKT two possibilities in regulating mTORC1 (Figure 
1.4.2).  
mTORC1 has two major downstream targets, p70S6K and 4EBP-1. Active mTORC1 
phosphorylates p70S6K on T389 and 4EBP-1 on T37/46. Besides T389 p70S6K has to be 
phosphorylated on S229/252 by PDK1 to be fully activated (Alessi et al., 1998; Pullen et 
al., 1998). Fully active p70S6K then activates ribosomal protein S6 via phosphorylation 
on S240/244. This finally promotes ribosome biogenesis and protein translation. It is 
obvious that this function of S6 is essential and as a result makes up to 30% of the total 
protein of a cell (Hengstschlager et al., 2001; Ma and Blenis, 2009; Miloloza et al., 2000; 
Proud, 2007; Shima et al., 1998; Toker, 2000). While phosphorylation of p70S6K is 
activating, the phosphorylation of 4EBP-1 by mTORC1 has an inhibitory effect. 
Phosphorylated 4EBP-1 dissociates from eIF4E, as unphosphorylated 4EBP-1 is bound to 
it and blocking translation. Free eIF4E is promoting the assembly of eIF4F complex and 
consequently mRNA translation, especially the cap-dependent translation (Dorrello et al., 
2006; Ma and Blenis, 2009; Raught et al., 2004; Shahbazian et al., 2006). 
Besides regulating translation and ribosome biogenesis, mTORC1 and mTORC2 are also 
a major regulators of cell size, growth and cell cycle (Rosner et al., 2009b). Knocking 
down rictor and raptor led to a severe decrease in cell size and reduced S-phase in cell 
cycle (Rosner et al., 2009b) and cells that do lack a functional mTORC1 do have smaller 
cells or the whole organism is smaller (Fingar et al., 2002; Kim et al., 2002). mTORC1 is 
also regulating autophagy, a special type of cell death, via ATG1 and p70S6K, and 
angiogenesis via HIF-1 and VEGF, insulin sensitivity, nutrient sensing, ageing and stress 
responses (Chiang and Abraham, 2007; Dunlop and Tee, 2009; Gwinn et al., 2008; 
Sabatini, 2006; Selman et al., 2009; Wei et al., 2009). 
Far less is known about mTORC2. Besides AKT mTORC2 has some other substrates e.g. 
PKCα and Rho (Ikenoue et al., 2008; Jacinto et al., 2006). In cells negative for rictor or 
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mSin1 phosphorylation and protein levels of PKCα are diminished. The phosphorylation 
of PKC through the components is essential for PKC kinase stability and function 
(Ikenoue et al., 2008). For a long time mTORC2 was thought to be rapamycin insensitive, 
in the recent years however several groups proved that long-term treatment with 
rapamycin leads to dissociation of the mTORC2 complex (Rosner et al., 2009b; Rosner 
and Hengstschlager, 2008; Sarbassov et al., 2006), and that this is mediated via 
dephosphorylation of rictor and mSin1 (Dunlop and Tee, 2009; Rosner and 
Hengstschlager, 2008). The role of the TSC1-TSC2 complex in regulating mTORC1 is 
known very well. Recent work revealed that cells lacking a functional TSC complex have 
an impaired activity towards AKT, a mTORC2 substrate. The reduced activity of AKT 
was shown to be independent of the negative feedback mechanism of p70S6K to IRS 
(Huang et al., 2008). It was found that TSC complex can physically associate with 
mTORC2 without involving Rheb, making it clear that there are major differences in the 
control of mTORC1 and mTORC2 (Huang et al., 2008). It was reported that mTORC2 
itself is a potent regulator of mammalian cell size and cell cycle via a mechanism 
involving the AKT/TSC2/Rheb cascade independently of mTORC1 (Rosner et al., 
2009b).  
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1.5 Tuberous sclerosis 
Tuberous sclerosis complex (TSC) is an autosomal dominant, multisystem genetic disease 
affecting 1 in 6000 births. Mutations in TSC1, encoding hamartin, or TSC2 gene, 
encoding tuberin, are causing TSC. It was first described by Bourneville in 1880. Table 
1.5.1 gives an overview of various clinical manifestations of tuberous sclerosis, which are 
important diagnostic criteria (Crino et al., 2006; Roach et al., 1998). For a definite clinical 
diagnosis of TSC two major features or one major and two minor features are required. 
For a probable, one major and one minor feature, and possible diagnosis, one major or 
two or more minor manifestations, are needed.  
Table 1.5.1 Diagnostic criteria for Tuberous Sclerosis 
 
 
Criteria Age at Onset
Major
cortical tuber fetal life
cardiac rhabdomyoma fetal life
retinal hamartoma infancy
hypomelanotic macule infancy to childhood
facial angiofibroma infancy to adulthood
shagreen patch childhood
subependymal nodule childhood to adolescence
subependymal giant-cell tumor childhood to adolescence
renal angiomyolipomas childhood to adulthood
ungual fibroma adolescence to adulthood
lymphangiomyomatosis adolescence to adulthood
Minor
multiple pits in dental enamel
bone cysts
hamartomatous rectal polyps
cerebral white-matter radial migartion lines
gingival fibromas
retinal achromic path
"confetti" skin lesions (groups of small pigmented spots)
multiple renal cysts
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The disease is often (>50%) accompanied by neurological disorders like autism, epilepsy 
and mental retardation. The neurological defects are also the primary cause of death 
among children (Kwiatkowski, 2003). The name of the disease, tuberous sclerosis, 
derives from the cortical tubers found in the brain of patients (Crino, 2004; Crino et al., 
2006; DiMario, 2004; Kwiatkowski and Manning, 2005). The pleiotropism of this 
syndrome is highlighted by the appearance of dysplastic lesions, called hamartomas, in 
several major organs (Shah and Hunter, 2005). Renal diseases are common in TSC 
patients, with an 80% chance to develop angiomyolipomas. Although malignant forms 
and renal cell carcinoma are rare, these lesions can be severe and manifest during early 
childhood (Bjornsson et al., 1996). In about 60-80% of affected individuals benign 
cardiac rhabdomyomas are detected perinatally, however they generally do regress during 
postnatal heart development (Crino et al., 2006; Shah and Hunter, 2005; Smythe et al., 
1990). Usually skin abnormalities are involved as well like angiofibromas and 
fibromatous plaques (Gomez et al., 1999). One clinical feature seems to probably be 
gender dependent namely pulmonary lymphangiomyomatosis (LAM), which appears 
more frequently in woman and is very rare in men (Kwiatkowski, 2003). When observing 
tuberous sclerosis in the perinatal period there is a high frequency of cardiac 
rhabdomyomas, arrhythmias, cerebral lesions and stillbirth in the fetus, whereas 
respiratory distress, arrhythmias, murmurs and cardiomegaly are the main signs in the 
neonate initially. The survival rate of patients diagnosed with TSC in the perinatal period 
is very low (21%) and as it is associated with a high incidence of morbidity and mortality 
(Isaacs, 2009). 
1.5.1 Genetics of TSC 
The tumor suppressor gene TSC1 is located on chromosome 9q34 and TSC2 on 
chromosome 16p13.3. As already stated above one mutation in either gene is sufficient to 
acquire TSC, and loss of heterozygosity has been documented in a wide variety of 
tumors. The development of a tumor is assumed to be the outcome of somatic “second 
hit” mutations according to the Knudson’s tumor suppressor model. Therefore, although 
TSC is considered an autosmal dominant disease, mutations in the TSC gene are believed 
to be recessive at the level of the affected cell (Crino et al., 2006; Kwiatkowski, 2003; 
Rosner et al., 2006). The majority of the disease-causing mutations occur de novo in 
either gene, and only about 1/3 of the TSC mutations are inherited. The distribution of 
mutations in TSC1 and TSC2 is about half in hereditary cases, however in sporadic TSC 
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mutations TSC2 stands out. TSC1 mutations are nearly always described as either 
nonsense or frameshift mutations leading to truncated hamartin protein. In TSC2 
mutations approximately 20% are missense or nonsense (Astrinidis and Henske, 2005; 
Rosner et al., 2008b).  
Tuberin and hamartin have to physically interact with each other to form a heterodimer 
(Figure 1.5.1) in order to be a functional complex (Plank et al., 1998; van Slegtenhorst et 
al., 1998). The two proteins are expressed within multiple organs in the same cell types 
including the brain, the kidney, lung and pancreas (Plank et al., 1999). So far there exists 
only one putative functional domain in tuberin, namely a GTPase activating protein 
(GAP) domain. Rheb, a member of the Ras family, was identified as the specific GTPase 
downstream of tuberin (Garami et al., 2003; Inoki et al., 2003).  
 
Figure 1.5.1 Domains and phosphorylation sites of hamartin and tuberin. a) 
Hamartin is a 1164 amino acid long protein with a molecular mass of 130kDa. It interacts 
with tuberin through amino acids 302-430 (Hodges et al., 2001). It is phosphorylated by 
CDK1/cyclinB1 at residues T417, S584 and T1047, and by GSK3ß at T357 and T390. b) 
Tuberin consists of 1807 amino acids and has a molecular mass of 200kDa. It interacts with 
hamartin through amino acids 1-418 (Hodges et al., 2001). Besides this domain tuberin has a 
GTPase activating protein (GAP) domain for Rheb. It is phosphrylated on S939 and T1462 
by AKT, at S1210 by MK2, at T1227 and S1345 by AMPK, from RSK2 at S1798 and by 
ERK at S664 (Astrinidis and Henske, 2005). 
 
1.5.2 Signaling pathway 
TSC is incorporated in some major signaling pathways by phosphorylation events that 
regulate tuberin’s GAP activity: PI3K-AKT pathway, the ERK1/2-RSK1 pathway and the 
LKB1-AMPK pathway (Figure 1.5.2). In brief, as some parts of the pathway were already 
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explained in previous sections, PI3K is being activated by growth factors and this in turn 
leads to activation of AKT. 
 
Figure 1.55.2 Upstream and downstream signaling events involving TSC (Rosner et al., 
2006). 
 
Akt has numerous downstream targets, to name some: the members of the FOXO family 
of transcription factors, BAD, GSK3α and β, members of the cip/kip family (p27 and 
p21), and last but not least tuberin (Downward, 2004; Manning and Cantley, 2003). AKT 
phosphorylation events are inhibitory in general and usually have survival promoting 
effects. In the absence of growth factors or other stimuli, the TSC1/TSC2 heterodimer has 
strong inhibitory effects towards Rheb (Ras homology enriched in brain) via its GAP 
(Saucedo et al., 2003; Stocker et al., 2003; Zhang et al., 2003). Upon induction of the 
pathway by growth factors, AKT phosphorylates tuberin on S939, S981, S1130,S1132 
and T1462, this in turn inhibits tuberin’s ability to block Rheb via its GAP activity (Dan 
et al., 2002; Inoki et al., 2002; Manning et al., 2002; Potter et al., 2002) and subsequently 
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Rheb-GTP levels increase (Tee et al., 2003). Elevated Rheb-GTP levels lead to the 
activation of the mTOR complex 1 (mTORC1), which is positively influencing 
translation and cell size / cell cycle regulation (Martin and Hall, 2005; Rosner et al., 
2009b; Tee and Blenis, 2005). Besides regulating mTOR and therefore indirectly cell size 
and cell cycle, tuberin can regulate the cell cycle independently of mTOR through the 
cyclin-dependent kinase inhibitor p27 (Rosner et al., 2006; Rosner and Hengstschlager, 
2004). Furthermore it does not only regulate p27, tuberin is influencing its stability and its 
localization (Rosner et al., 2009a; Rosner et al., 2006; Rosner and Hengstschlager, 2004). 
In summary, tuberin is a potent regulator of the PI3K-AKT pathway, regulating cell size, 
cell cycle, translation and apoptosis. 
 
1.6 PRAS40 
In 2003 Kovacina et al. identified a novel substrate for AKT called proline-rich AKT 
substrate of 40kDa (PRAS40) binding 14-3-3 proteins. They showed that PRAS40 was 
phosphorylated by AKT in vitro at the same site that was phosphorylated in insulin 
treated cells. Secondly, the activation of an inducible AKT was sufficient to stimulate its 
phosphorylation. Lastly, the phosphorylation of PRAS40 was diminished in cells lacking 
AKT1 and AKT2, demonstrating that PRAS40 is indeed a substrate of AKT (Kovacina et 
al., 2003). Later, other groups recognized that PRAS40 is also an mTORC1 complex 
component (Oshiro et al., 2007; Sancak et al., 2007; Thedieck et al., 2007; Vander Haar et 
al., 2007), preferentially binding to raptor but also to mTOR protein itself. However, 
PRAS40 is not binding to rictor and therefore is not involved in mTORC2 regulation 
(Oshiro et al., 2007; Sancak et al., 2007; Thedieck et al., 2007; Vander Haar et al., 2007) 
1.6.1 PRAS40 genetics 
PRAS40 gene is located on chromosome 19q13.33 and encodes for three different 
transcript variants that are all consisting of 256 amino acids but do differ in the 5’-UTR. 
The highest transcription levels of PRAS40 are found in human liver, heart, and placenta 
(Kovacina et al., 2003; Nascimento et al., 2006). As the name suggests the protein 
consists of a proline-rich sequence at the amino terminal domain (Kovacina et al., 2003). 
This region is followed by two motifs, the TOS (mTOR signaling) and the RAIP motif 
(Figure 1.6.1), that have been implicated for mTORC1 binding and phosphorylation of its 
substrates (Nascimento and Ouwens, 2009).  
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Figure 1.6.1 Primary structure of the PRAS40 protein. PRAS40 consists of two proline-rich 
stretches followed by a TOS-motif, a RAIP-motif and a NES. Arrows indicate phosphorylation 
sites of PRAS40 by AKT, mTORC1 and other kinases (Nascimento and Ouwens, 2009). 
 
PRAS40 is a highly conserved protein and the TOS, RAIP and NES-motifs as well as the 
phosphorylation sites on S183, S221 and T246 share high homology (Vander Haar et al., 
2007). The TOS motif is found in many other substrates for mTORC1 and the RAIP 
motif is also found in 4EBP1 (Beugnet et al., 2003; Tee and Proud, 2002).  
1.6.2 Cellular functions of PRAS40 
There are different opinions on the role of PRAS40 in the mTOR signaling pathway, 
ranging from PRAS40 being an inhibitor of mTORC1 (Sancak et al., 2007; Wang et al., 
2007), a substrate of mTORC1 (Fonseca et al., 2007; Oshiro et al., 2007; Vander Haar et 
al., 2007) or both. However, before placing PRAS40 in the mTORC1 signaling pathway, 
it was found to be a new substrate for AKT, which is phosphorylating it on T246 
(Kovacina et al., 2003). The regulation of PRAS40 T246 phosphorylation by AKT seems 
to be dependent on AKT S473 phosphorylation through mTORC2. Inhibition of 
mTORC2 activity, by silencing rictor or pharmacologically, reduces T246 
phosphorylation of PRAS40 (Thedieck et al., 2007; Toschi et al., 2009). Recently it was 
shown that the serine/threonine kinase PIM1, playing a role in cell survival, proliferation 
and differentiation, is also able to phosphorylate PRAS40 on T246. Furthermore PIM1’s 
ability to phosphorylate PRAS40 on that site is independent from AKT and not inhibited 
by wortmannin. The investigators suggests that PIM1 regulated mTORC1 acvitiy via 
phosphorylation of PRAS40 (Zhang et al., 2009). As stated above PRAS40 is not only an 
inhibitor of mTORC1, it is also a substrate for mTORC1 (Figure 1.6.2). Several different 
phosphorylation sites for mTORC1 on PRAS40 exist: S183, S202/203, S212 and S221 
(Oshiro et al., 2007; Wang et al., 2008). The phosphorylation of S183 is promoted by 
amino acids and insulin and is reduced by the addition of rapamycin strongly supporting 
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that mTORC1 is the kinase for this site (Oshiro et al., 2007; Wang et al., 2008). From all 
the other phoyphorylation sites, in addition to S183, only S221 is also sensitive to 
rapamycin (Wang et al., 2008). The kinases that phosphorylate PRAS40 on these other 
sites yet have to be identified.  
 
Figure 1.66.2 Regulation of mTORC1 by insulin, amino acids, glucose and energy 
deprivation. The activation of mTORC1 requires the binding of Rag and Rheb to mTORC1. Full 
activation of mTORC1 further requires the dissociation of PRAS40 from mTORC1, which 
requires phosphorylation of PRAS40 by both AKT and mTORC1 and 14-3-3 binding 
(Nascimento and Ouwens, 2009). 
 
Consistent with a role for PRAS40 as a negative regulator of mTORC1, ectopic 
expression of PRAS40 led to a significant reduction of cell size (Sancak et al., 2007; 
Vander Haar et al., 2007). Reciprocally, the silencing of PRAS40 led to an increased cell 
size in drosophila (Sancak et al., 2007). The inhibitory function of PRAS40 seems to be 
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partly dependent on the interaction with raptor, supposedly via the TOS motif and S183, 
the location of the RAIP motif. Based on this it was proposed that PRAS40 functions as 
an inhibitor of substrate binding on raptor (Oshiro et al., 2007; Wang et al., 2007). There 
exist contradictory data about the downstream effect of silencing PRAS40; some groups 
found an upregulation of S6K1 and 4EBP1 phosphorylation upon PRAS40 silencing 
(Oshiro et al., 2007), however others report that both amino acid and insulin induced 
phosphorylation of S6K1 and 4EBP1 are reduced in the absence of PRAS40 (Fonseca et 
al., 2007; Vander Haar et al., 2007; Wang et al., 2007). The requirement of PRAS40 for 
the phosphorylation of mTORC1 substrates, therefore, also suggests a role for PRAS40 in 
the assembly or integrity of the mTORC1 complex (Nascimento and Ouwens, 2009).  
Another regulatory function of PRAS40 is a role in cell survival and apoptosis. When 
overexpressed it protects neurons from apoptotic cell death, transient focal cerebral 
ischemia or spinal cord injury (Saito et al., 2004; Yu et al., 2008). On the other hand, 
silencing PRAS40 expression has been found to protect against the induction of apoptosis 
by TNFα or cyclohexamide (Thedieck et al., 2007). It is important to note that rapamycin 
fails to mimic the proapototic effect of PRAS40 silencing and therefore it has been 
suggested that PRAS40 may regulate apoptosis independently of mTORC1 (Thedieck et 
al., 2007).  
Not that much is known about PRAS40 and diseases. In pre-malignant and malignant 
breast and lung cancer cell lines both, PRAS40 and phosphorylation on T246 are elevated 
(Huang and Porter, 2005). Furthermore, PRAS40 T246 levels were elevated in 
meningiomas and malignant melanomas (Johnson et al., 2009; Madhunapantula et al., 
2007). Interestingly, lowering PRAS40 T246 associates with an increased sensitivity of 
tumor cells to pro-apoptotic stimuli, suggesting that PRAS40 does play a critical role in 
tumor cell survival (Madhunapantula et al., 2007).  
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2. MATERIALS AND METHODS 
2.1 Cell culture 
All cell lines used during this thesis were incubated at 5% CO2 and 37°C in a Heraeus 
BBD 6220 incubator (Thermo Scientific, Waltham, MA, USA). All cell lines were 
obtained from the American Type Culture Collection (ATCC) unless we kindly received 
them from other colleagues (see in the text). 
2.1.1 Cell lines 
The human non transformed, non immortalized, primary fetal lung fibroblasts IMR-90 
were grown in DMEM-HG medium. The cell lines MCF-7 (mammary gland 
adenocarcinoma) and Hela (epithelial cervix carcinoma) were also grown in DMEM-HG 
medium supplemented with 10 % FCS and antibiotics 30 mg/l penicillin, 50 mg/l 
streptomycin sulphate and 2.5 mM L-glutamine. The Jurkat T cells (human T cells 
leukemia) are suspension cells and were grown in DMEM-HG medium supplemented 
with 10 % FCS and 2,5 mM L-glutamine. SK-N-SH cells (human neuroblastoma) were 
cultured in RPMI medium supplemented with 20 % FCS, antibiotics and 2,5 mM L-
glutamine. Cells used for immunofluorescence staining, were seeded and cultured on 
either glass or permanox slides. Mouse embryonic kidneys (E11.5) were dissected, grown 
and stained as described (Siegel et al., 2010; Unbekandt and Davies, 2010). Cells were 
routinely screened for mycoplasma. 
2.1.2 hAFS cells 
The human AFS cell line Q1 has been established by Anthony Atala via magnetic cell 
sorting using the CD117 MicroBead Kit (De Coppi et al., 2007). AFS cells were grown in 
α-MEM minimal essential medium (Gibco-Invitrogen, Carlsbad, CA, USA, 41061), 
supplemented with 15 % ES-FCS (HyClone, Waltham, MA, USA, 30070.03), 18 % 
Chang B, 2 % Chang C (Irvine Scientific, CA, USA, C100, C106), 2,5 mM L-glutamine, 
50 mg/l streptomycin sulphate and 30 mg/l penicillin. The Q1 hAFS cell line was 
cytogenetically analyzed according to standard protocols. Chromosome banding was 
produced by means of a conventional 550-band trypsin-Giemsa analysis. A significant 
number of metaphases were analyzed for numerical and structural chromosome 
aberrations (Hengstschlager et al., 2005). 
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2.1.3 Cell culture methods 
2.1.3.1 Thawing of cells 
All cells are stored in a liquid nitrogen tank. For thawing cells cryo tubes need to be taken 
from the tank and rapidly transferred to a 37°C water bath. After thawing the cell 
suspension is transferred from the cryo tube into a 15ml Falcon tube filled with 1- 5ml of 
pre-warmed cell culture medium and centrifuged at 1000rpm for 3 to 5 minutes. The 
supernatant is discarded and the cell pellet is resuspended in the appropriate cell culture 
medium and seeded into a cell culture dish. 
2.1.3.2 Harvesting cells 
The culture medium is discarded and then cells are washed once with 1x PBS. The PBS 
needs to be removed and depending on the size of the cell culture dish an appropriate 
amount of Trypsin-EDTA is added to the cells and  incubated at 37°C for a maximum of 5 
minutes. Then the trypsin is inactivated by adding at least two times the amount of 
medium containing 10% FCS of trypsin used. Cells are transferred to a 15ml falcon tube 
and centrifuged for 5  minutes at 1000rpm. 
2.1.3.3 Passaging of cells 
Cells were harvested as described and the resulting pellet is resuspended in an appropriate 
amount of medium and transferred into new cell culture plates at an appropriate splitting 
ratio. 
2.1.3.4 Freezing of cells 
Cells were harvest like in 2.1.3.2 and the obtained pellet is resuspended in 900µl of the 
appropriate medium. Prior to this cryo tubes need to be prepared containing 100µl (10%) 
of DMSO. The cell suspension is then added to the  100µl of DMSO and the tube is 
inverted 3 to 6 times and stored on ice immediately afterwards. After a 20 minutes pre-
incubation period on ice the cryo tube is then transferred to -80°C and is stored there for 
24 to 72 hours. At last the cryo tube is put into the liquid nitrogen tank for long term 
storage of the cells. 
 
 
 
36 
 
2.1.4 Embryoid bodies 
2.1.4.1 Preparation of methylcellulose 
Methylcellulose is a component of the EB medium, which additionally prevents cells 
from attaching to the bottom of a 96-Well-Plate. 7,5g of methylcellulose (cat# m-0512) 
are filled into a 500ml bottle containing a magnetic stirrer and then the methylcellulose is 
autoclaved. The powder is dissolved in 250ml of preheated basal medium (60°C) for 20 
minutes. After dissolving the powder another 250ml of basal medium, having room 
temperature, is added to a final volume of 500ml and is mixed over night at 4°C on a 
magnetic stirrer. Aliquot the stock solution into 50ml falcons and then clear the 
methylcellulose by centrifugation at 5000g for 2h at room temperature. Only transfer the 
clear highly viscous supernatant (90-95% of the stock solution) into 50ml falcon tubes 
and store aliquots at -20°C. 
2.1.4.2 EB formation 
EBs were generated using a suspension method with 0,3% (v/v) methylcellulose in 96-
well plates with a U shape and non-adhesive cell culture plastic (PAA, Linz, Austria, 
34296X) as described (Valli et al., 2010). A single EB is composed of 1000 to 1500 cells 
in 100 µl medium. 
2.1.4.3 Harvesting EB 
For protein extraction whole EBs were harvested. For analysis of cell number and cell 
size / DNA content EBs were harvested, washed 3 times in ice cold 1x PBS and then 
trypsinized for 15-20 minutes to receive a single cell suspension. Separating the inner and 
outer cells of EBs was achieved by harvesting EBs, washing them carefully with ice cold 
1x PBS, followed by a 2-3 minute incubation with Trypsin-EDTA. Reaction was stopped 
by adding medium to EBs. EBs and single cells (outer cells) were separated by slow 
centrifugation (300 rpm, 5 minutes, 4°C). Supernatant was collected, transferred into new 
tubes and centrifuged for 10 minutes, 1000 rpm at 4°C. Cell pellet was then used for 
further analysis. Remaining EBs were washed with 1x PBS and then trypsinized for 15-20 
minutes to receive single cells (inner cells). So obtained cell pellets were further 
processed for analysis. 
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2.1.5 siRNA transfection of cells 
RNA silencing was achieved using human siRNA specific for PRAS40, tuberin and 
mTOR (Dharmacon, Lafayette, CO, USA) at a final concentration of 50 nM (Rosner et 
al., 2010). siRNA was delivered to cells using RNAiMAX reagent (Invitrogen). A pool of 
four non-targeting siRNAs was used as control for non –sequence-specific effects for 
each transfection. Analysis and EB formation was performed 72 h after transfection. 
2.1.6 DNA transfection of cells 
For transfection of cells with plasmid DNA cells need to be grown in antibiotic free 
medium at a density of 80-90% at the time of transfection and cells need to be seeded 16-
24h before transfection. For one 6-Well 1µg of plasmid DNA has to be diluted in 150µl 
OptiMEM medium and is mixed gently. The second solution consists of 3,75µl 
Lipofectamine 2000 reagent in 150µl of OptiMEM. Mix both solutions together and mix 
gently using a vortexer. Incubation time for the DNA-Lipofecatmine solution is at least 
20 minutes. Then formed complexes are added to the cells. Cells can be harvested and 
analyzed 24 to 48 hours after transfection.  
Table 2.1.1 Plasmids used for transfections 
 
 
 
2.1.7 Treatment of cells with chemical compounds 
2.1.7.1 Rapamycin treatment 
The mTOR specific inhibitor rapamycin (Calbiochem, La Jolla, CA, USA, 553211) is 
added to the medium at a final concentration of 100nM for 24h, unless otherwise stated, 
before harvesting the cells. Control cells are treated with the equal amount of DMSO. 
 
Gene Vector backbone Tag cataloge # company
PRAS40 pcDNA3.1(+) myc kindly provided by R. A. Roth
PRAS40 S183A pcDNA3.1(+) HA #15674 Addgene
empty pcDNA3.1(+) #V790-20 Invitrogen
PRAS40 pRK5 myc #15476 Addgene
PRAS40 T246A pRK5 myc #15479 Addgene
empty pRK7 kindly provided by J. Blenis
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2.1.7.2 Wortmannin treatment 
Wortmannin is a PI3K inhibitor and therefore blocks phosphorylation of AKT, PRAS40 
and Tuberin for example. Before the inhibitor is added, cells are starved for 16 hours or 
overnight with 0% FCS medium. Then Wortmannin is added to a final concentration of 
10µM to the cells for 30 minutes. For control cells an equal amount of DMSO is added. 
After the incubation, serum is added to the cells to reach a final concentration of 10% 
FCS. Cells are incubated for another 30 minutes. Then cells can be harvested for further 
investigation. 
 
2.2 Isolation, preparation and analysis 
2.2.1 Protein extraction 
Total protein was extracted by physical disruption of cell membranes by repeated freeze 
and thaw cycles. In brief, cells/EBs were washed with PBS and harvested after 
trypsinization. Cell pellets were lysed in buffer A containing 20 mM Hepes pH 7,9, 0,4 M 
NaCl, 2,5 % glycerol, 1 mM EDTA, 0,5 mM DTT, 1 mM PMSF, 0,5 mM NaF, 0,5 mM 
Na3VO4 supplemented with 2 µg/ml aprotinin, 2 µg/ml leupeptin, 0,3 µg/ml 
benzamidinchlorid, 10 µg/ml trypsininhibitor by repeated freeze and thaw cycles. After 
incubation on ice and centrifugation at 15000 rpm for 20 minutes at 4°C supernatants 
were collected and protein lysates stored at -80°C. Protein concentrations were 
determined using Bio-Rad protein assay (Rosner and Hengstschlager, 2008). 
2.2.2 Cytoplasmic and nuclear fractionation 
For cytoplasmic and nuclear fraction of proteins everything is the same as in 3.2.1 until 
the second wash step. The pellet gets resuspended in 500µl of 1xPBS and transfer 100µl 
of the suspension into a tube for the total protein lysate and the rest into another tube for 
the cytoplasmic-nuclear preparation. For total protein extraction see section 2.2.1. After 
the third washing step resuspend the pellet in 5x volume of lysis buffer F1 and incubate 
2min at RT, followed by 10 minutes incubation on ice. After incubation NP-40 is added at 
a final concentration of 1% (v/v) and lysates are homogenized by passing through a 20-
gauge needle for three times. Nuclei are pelleted by centrifugation at 2500rpm for 5 
minutes at 4°C and supernatant containing cytoplasmic proteins is collected. Remaining 
nuclei are washed three times with buffer F containing 1% NP-40. The nucleic pellets are 
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lysed in buffer A by repeated freeze and thaw cycles. Supernatant containing the soluble 
nuclear proteins is collected by centrifugation at 15000rpm at 4°C for 20 minutes (Rosner 
et al., 2007b; Rosner and Hengstschlager, 2007). 
2.2.3 Flow cytometry and CASY cell counter 
EBs were processed as described above to receive single cells. Cells were fixed by rapid 
submersion in ice-cold 85% ethanol. After fixation over night at -20°C DNA was stained 
with 0,25 mg/ml propidium iodide, 0,05 mg/ml RNAse A, 0,1% Triton X-100 in citrate 
buffer, pH 7,8 and cell size (FSC) and subG1 fraction was analyzed on a Beckton 
Dickinson FACSCalibur (Beckton Dickinson, San Jose, CA, USA) (Rosner et al., 2003). 
For flow cytometric analysis a 96-well plate with EBs was used in triplicate. For cell 
number determination EBs were trypsinized to obtain single cells and then determined on 
a Casy Cell Counter (Innovatis). For each measurement 32 EBs were trypsinized to 
calculate the cell number of a single EB and was performed in triplicate. 
 
2.2.4 Immunocytochemistry 
2.2.4.1 Preparation of 4% Paraformaldehyde (PFA) 
Dissolve 20g of PFA in 250ml ddH2O. Add 5ml of 1M NaOH and stir on a magnetic 
stirrer at 65°C until all PFA has dissolved. Then add 50ml of 10x PBS to the solution and 
let cool down to room temperature. Adjust the pH to 7,4 with 37% HCl, add another 
100ml ddH2O. Sterile filtrate the solution and make 5-10ml aliquots. These can be stored 
at -20°C. 
2.2.4.2 Immunocytochemistry of cells 
Cells on slides were incubated with 4% PFA for 10 minutes at room temperature. Fixed 
cells were washed with PBS and then first blocked with 0,1% Triton X-100 in PBS for 10 
minutes, followed by a second block with 0,5% BSA in PBS/T for 30 minutes at room 
temperature. After blocking cells were subsequently stained with primary antibody over 
night at 4°C. Antibodies specific for the following proteins (also see Table 2.2.1) were 
used: anti-α-fetoprotein (αFP) antibody (R&D Systems MAB4305), anti-laminin antibody 
(Sigma L9393), anti-nestin antibody (Neuromics MO15012), and anti-WT1 antibody 
(Dako M3561). After staining with primary antibody cells were washed with PBS and 
incubated with labeled secondary antibody (1:100 in PBS) for 30 minutes at room 
temperature: goat TRITC α-rabbit (Sigma) or goat FITC α-mouse (Sigma). Cells were 
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washed again and DAPI (4,6-diamino-2-phenylindole; 1µg/ml) was added for nuclei 
staining. 
 
Table 2.2.1 Antibodies used for immunofluorescence stainings 
 
 
2.2.4.3 Immunocytochemistry of EB 
For immunofluorescence stainings of EBs they were incubated with 4% 
paraformaldehyde for 30 minutes at room temperature and then carefully washed with 
PBS, followed by washing 15 minutes in TBS/T and subsequently 15 minutes in PBS/T. 
EBs were blocked for 1 hour in 1 %  BSA in PBS/T. EBs were washed and stained with 
primary antibody over night at 4°C. Antibodies specific for the following proteins were 
used: αFP (R&D Systems), nestin (Neuromics), and WT1 (Dako). After primary antibody 
staining EBs were washed and afterwards stained with labeled secondary antibody: Alexa 
Fluor 488 goat α-mouse (Molecular Probes – Invitrogen A11029) and DAPI over night at 
4°C. The next day stained EBs were washed three times with 1x PBS and then transferred 
onto glass slides. Images were obtained with a Zeiss LSM Exciter confocal microscope 
(Carl Zeiss, Oberkochen, Germany).  
 
 
Antibody Host Dilution Company
αFP mouse 1:100 R&D Systems
Laminin rabbit 1:50 Sigma-Aldrich
Nestin mouse 1:200 Neuromics
WT-1 mouse 1:50 Dako
Alexa Fluor 488 mouse goat 1:400 Molecular Probes, Invitrogen
Alexa Fluor 546 rabbit donkey 1:400 Molecular Probes, Invitrogen
Mouse-FITC goat 1:100 Sigma-Aldrich
Rabbit-TRITC goat 1:100 Sigma-Aldrich
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2.2.5 HOPI (Hoechst propidium iodide) staining 
Cell culture medium with a final concentration of 5 µg/ml Hoechst dye (HO) and 2µg/ml 
propidium iodide (PI) was prepared. Control and treated cells were washed with PBS and 
treated with TE. The trypsinized cells were harvested in an Eppendorf tube and incubated 
with the HOPI stain and medium for 1hour at 37°C. After incubation the cells need to be 
carefully resuspended to receive a single cell solution. Then 1 drop was put on a glass 
slide and pictures were taken with the Olympus microscope (up to ten pictures per 
sample). EBs (Fig. 2A) were directly incubated with the HOPI dye in a 96-well plate and 
were analyzed on a confocal microscope after 1 h incubation. The analysis of stained cells 
was done by counting viable, apoptotic and necrotic cells. The Hoechst 33258 dye stains 
the nuclei of all cells. Nuclear changes, such as chromatin condensation and nuclear 
fragmentation, are associated with apoptosis. PI uptake indicates loss of membrane 
integrity being characteristic for necrosis and apoptosis. Necrosis is characterized by 
nuclear PI uptake into cells without chromatin condensation or nuclear fragmentation 
(Grusch et al., 2002) 
 
2.2.6 Immunoblotting 
Proteins were run on a SDS-Polyacrylamide gel and transferred onto a nitrocellulose 
membrane. Blots were stained with Ponceau-S to visualize the amount of loaded protein. 
For immunodetection, antibodies specific for the following proteins were used: tuberin 
(Santa Cruz Biotechnology, sc-892), phospho-PRAS40 T246 (Cell Signaling, 2997), 
PRAS40 (Cell Signaling, 2691), mTOR (Cell Signaling, 2972), phospho-p70S6K T389 
(Cell Signaling, 9234), p70S6K (Cell Signaling, 9202), α-Tubulin (Calbiochem, CP06), 
GAPDH (Trevigen, 2275-PC-100). Rabbit polyclonal and monoclonal antibodies were 
detected using anti rabbit IgG, an HRP-linked heavy and light chain antibody from goat 
(A120-101P, Bethyl Laboratories); mouse monoclonal antibodies were detected using 
anti-mouse IgG, an HRP-linked heavy and light chain antibody from goat (A90-116P, 
Bethyl Laboratories). Signals were detected using the enhanced chemiluminescence 
method (Pierce).  
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2.2.7 Microscopy 
For phase contrast images EBs were photographed with an Olympus IX51 equipped with 
a XC50 camera (Olympus, Tokio, Japan). For the measurements of the “inner area” and 
“whole area” of EBs pictures were randomly taken from three 96-well plates and the area 
was determined using the microscopic imaging software Cell^D (Olympus, Tokyo, 
Japan). The inner area of the EB is defined as the round shaped inner structure. The cells 
situated out of the inner EB are integrated in the measurement of the “whole EB” (for a 
scheme see Figure 3.2.3). All immunostained samples were analyzed on either an 
Olympus IX51 microscope with a XC50 camera (Olympus, Tokio, Japan) or a Zeiss LSM 
Exciter confocal microscope (Carl Zeiss, Oberkochen, Germany). The microscopes were 
not changed within one experiment. 
2.2.8 Statistical analysis 
Analysis of “inner” and “outer” (whole) area of EBs, flow cytometry data, EB formation 
and cell number data are all presented as average ± standard deviation (SD). All 
comparisons between groups were calculated using Student’s t-test (unpaired, two-tailed) 
with P-values ≤ 0,05 indicating statistical significance. 
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3. RESULTS 
3.1 The localization of PRAS40 
Researchers exploring the mTOR signaling pathway are mainly investigating the 
biochemistry of this complex and its regulation. In the recent years, it got more and more 
popular to get insights into the localization of the complex proteins, its upstream 
regulators and downstream substrates (Rosner and Hengstschlager, 2008). Additionally, 
the localization of proteins can be regulated by other proteins e.g. via phosphorylation 
(Rosner et al., 2007a). As PRAS40 was found to be a new negative regulator of mTORC1 
and additionally a substrate for the same complex, we wanted to investigate PRAS40’s 
localization. 
For cytoplasmic and nuclear fractionation logarithmically growing IMR-90 or Hek293 
cells were used. The purity of the obtained fractions was investigated by analyzing the 
expression of α-tubulin (cytoplasmic) and topoisomerase IIβ (nuclear). It was of 
importance to use primary, non immortalized, human fetal lung fibroblasts as our cell 
system of choice, as they resemble the human cell and tissue system in the closest way. In 
addition, we performed some of the experiments in Hek293 cells, because these cells are 
widely used by the scientific community.  
We found that PRAS40 localization is similar to other mTOR pathway proteins e.g. AKT, 
mTOR, tuberin, namely primarily in the cytoplasm (Rosner et al., 2007a; Rosner et al., 
2007b; Rosner and Hengstschlager, 2008). Only a very small fraction of the total PRAS40 
protein is localized to the nucleus (Figure 3.1.1). 
To analyze where active PRAS40 phosphorylated on Thr246 is localized, we had to test 
the specificity of the phospho-antibody. First we checked if the antibody could recognize 
the phosphorylation state at all. Phosphorylation of PRAS40 can be inhibited by the well 
known PI3K inhibitor Wortmannin (100nM), which concomitantly inhibits 
phosphorylation of AKT on Ser473. We used three different cell lines to test whether the 
antibody was able to recognize the phosphorylation state of the protein (Figure 3.1.2 A). 
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Figure 3.1.1 PRAS40 is predominantly localized to the cytoplasm. Logarithmically growing 
IMR-90 fibroblasts were lysed and proteins were prepared to obtain either total cell lysates (TL) 
or cytoplasmic (C) and nuclear (N) fractions. Purity of fractions was demonstrated by using α- 
tubulin (C) and topoisomerase IIß (topo IIß) (N) antibodies. Localization of total PRAS40 protein 
was analyzed.  
 
Secondly we had to prove that the antibody specifically recons the phosphorylation site 
on Thr246. This was done by overexpressing WT and mutated (T246A) PRAS40 in IMR-
90 cells and analyzing total and phosphorylated PRAS40 on a Western blot (Figure 3.1.2 
B). The results proved that the here used antibody specifically recognizes PRAS40 
phosphorylated on Thr246. 
 
Figure 3.1.2 The phospho-PRAS40 T246 antibody specifically recognizes the 
phosphorylated protein and is site specific. A) Logarithmically growing IMR-90, NIH 3T3 and 
Hek293 cells were starved of serum over night, treated with or without Wortmannin (100nM) for 
30 minutes and were stimulated with serum at a final concentration of 10% (v/v) and directly 
lysed afterwards. Expression levels of pospho-PRAS40 T246, phospho-AKT S473 and total AKT 
were analyzed on a Western blot. α-tubulin served as a loading control. B) IMR-90 cells were 
transfected with either wild type PRAS40 (PRAS40 WT) or a mutated form of PRAS40’s 
phosphorylation site in T246 (PRAS40 T246A) as indicated in the Materials and methods section. 
Whole cell lysates were prepared and protein expression of phosphor-PRAS40 T246 and total 
PRAS40 was analyzed. α-tubulin served as a control of equal loading. 
IMR-90
α- PRAS40
α- topo IIß
α- α- tubulin
α- phospho PRAS40 T246
α- phospho AKT S473
α- AKT
α-α-tubulin
- + - + - + Wortmannin
IMR-90 NIH 3T3 Hek293
B)A)
IMR-90
α- phospho PRAS40 T246
α- PRAS40
α- α- tubulin
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Analyzing phosphorylated PRAS40 on Thr246 on a Western blot we could demonstrate 
that it is localized the same way as the total protein in logarithmically growing IMR-90 
cells (Figure 3.1.3) and also in logarithmically growing Hek293 cells (data not shown).  
 
Figure 3.1.3 Phosphorylated PRAS40 is localized mainly to the cytoplasm. Logarithmically 
growing IMR-90 cells were lysed and proteins were prepared to obtain wither whole cell lysates 
(TL) or cytoplasmic (C) and nuclear (N) fractions. Purity of fractions was demonstrated by using 
α- tubulin (C) and topoisomerase IIß (N) antibodies. Localization of phosphorylated PRAS40 at 
T246 was analyzed.  
 
The next step was to identify, if the localization of the PRAS40 protein is dependent on 
its phosphorylation site on Thr246. Therefore we transiently overexpressed wild type and 
mutant (T246A) PRAS40 in IMR-90 cells for 48h using a lipid based transfection method 
(Figure 3.1.4). Wild type and mutant (T246A) PRAS40 protein was ectopically expressed 
to similar levels as can be seen in total lysates of cells analyzed (Figure 3.1.4 left panel). 
Cytoplasmic and nuclear fractions were obtained and analyzed by Western blot. From the 
obtained results of these experiments we can say that phosphorylated PRAS40 on Thr246 
is localized the same way as wild type PRAS40 ectopically expressed in IMR-90 (Figure 
3.1.4). 
α- topo IIß
α- α- tubulin
α- phospho PRAS40 T246
IMR-90
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Figure 3.1.4 PRAS40 phosphorylation at T246 is not essential for PRAS40 localization. 
Total lysates of IMR-90 cells expressing either corresponding empty vector, wild type PRAS40 
(PRAS40 WT) or mutant PRAS40 (PRAS40 T246A) were analyzed on a Western blot for 
expression of PRAS40 protein. α- tubulin served as control for equal loading of proteins (left 
panel). From the same transfected IMR-90 cells cytoplasmic and nuclear fractions were obtained. 
α- tubulin (C) and topo IIß (N) served as controls for purity of obtained fractions. Localization of 
total PRAS40 protein was analyzed (right panel). 
 
For another phosphorylation site of PRAS40, namely S183, only the ectopic mutant 
(PRAS40 S183A) localization experiments could be done do to the lack of a suitable 
antibody. Secondly the experiments were only conducted in Hek293 cells, as the ectopic 
expression of the plasmid only yielded satisfying transfection efficiency in this cell line. 
Western blots of wild type or mutant (S183A) PRAS40 transiently transfected Hek293 
cells (Figure 3.1.5) showed that we were able to overexpress PRAS40 protein. However 
the mutated form of PRAS40 on S183 was expressed at lower levels than ectopic wild 
type PRAS40. At least from Hek293 cells we can say that phosphorylated PRAS40 on 
S183 seems to be dispensable for proper or rather normal localization of PRAS40 protein 
as we could not detect a change in the localization of total PRAS40 protein.   
α- PRAS40
α- topo IIß
α- α- tubulin
Cytoplasm Nucleus
IMR-90
α- PRAS40 (short exposure)
α- PRAS40 (long exposure)
α- α- tubulin
IMR-90
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Figure 3.1.5 PRAS40 phosphorylation at S183 is not essential for localization of PRAS40 
protein. Total lysates of Hek293 cells expressing either corresponding empty vector, wild type 
PRAS40 (PRAS40 WT) or mutant PRAS40 (PRAS40 S183A) were analyzed on a Western blot 
for expression of PRAS40 protein. α- tubulin served as control for equal loading of proteins (left 
panel). From the same transfected Hek293 cells cytoplasmic and nuclear fractions were obtained. 
α- tubulin (C) and topo IIß (N) served as controls for purity of obtained fractions. Localization of 
total PRAS40 protein was analyzed (right panel). 
 
To summarize the results we can say that PRAS40 is predominantly localized to the 
cytoplasm in logarithmically growing IMR-90 firboblasts and Hek293 cells. Second that 
PRAS40 total protein localization is not dependent on its phosphorylation sites on Thr246 
or Ser183 when ectopically expressed. At last, from the results obtained from the 
experiments conducted so far, AKT-mediated phosphorylation on T246 does not affect 
PRAS40 cytoplasmic and nuclear localization. 
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α- PRAS40
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3.2 PRAS40 and TSC2 regulate apoptosis during early development of 
embryoid bodies via mTOR 
Two major branches are currently investigated in our laboratory, namely the mTOR 
signaling pathway and hAFS cells and their potential. In the past few years we started to 
combine those two to study the mTOR pathway and its role in hAFS cells and their 
differentiation (Rosner et al., 2008a; Siegel et al., 2010; Siegel et al., 2009; Valli et al., 
2010). The two major upstream regulators of mTORC1 are tuberin (TSC2), via regulating 
Rheb, and proline rich AKT substrate of 40kDA (PRAS40) in a more direct way (Dunlop 
and Tee, 2009; Inoki et al., 2003; Sancak et al., 2007). One model system to study 
development and differentiation are so called EBs, which are three dimensional cell 
aggregates composed of stem cells. The following results will give new insights about the 
role of PRAS40 and TSC2 in the development of EBs derived from hAFS cells. 
The study was done in Q1 cells, which have already been used in previous studies 
(Rosner et al., 2010; Siegel et al., 2010; Siegel et al., 2009; Valli et al., 2010). They are a 
monoclonal hAFS cell line, which were kindly provided by Anthony Atala. Handling of 
cells, EB formation and other methods used for generating these results can be found in 
the materials and methods section of this thesis. To study the role of PRAS40 and TSC2 
in EBs siRNA knockdown technology was chosen, as our laboratory could demonstrate it 
to be a very efficient tool and knockdowns can be kept up to 15-21 days depending on the 
cell line (Rosner et al., 2010).  
Q1 cells were transfected with non targeting control, human specific PRAS40 or human 
specific TSC2 siRNAs at a final concentration of 50nM. To prove that the siRNA 
treatement was successful protein lysates of treated Q1 cells were prepared. Western blot 
analysis shows efficient knockdown of endogenous TSC2 (tuberin) and PRAS40 protein. 
To ensure equal loading of protein samples α-tubulin served as control (Figure 3.2.1). 
Then EBs consisting of approximately 1000-1500 cells were formed, choosing a 
suspension culture method with methylcellulose as previously published (Valli et al., 
2010). After 24h (day 1) EBs were analyzed morphologically and by measuring EB 
formation efficiency, area and cell number. 
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Figure 3.2.1 Monoclonal Q1 human AFS cells were transfected with non-targeting control 
siRNA, TSC2-specific siRNA or PRAS40-specific siRNA and knockdown of endogenous tuberin 
and PRAS40 was confirmed by Western blot analysis. α-tubulin served as a control for equal 
loading. 
 
One parameter we analyzed was the efficiency of EB formation. One day post start of EB 
formation the efficiency was approximately the same in all EBs indicating that the 
formation of EBs per se was not impaired due to knockdown of PRAS40 or TSC2. 
However 6 days post EB formation the stability / efficiency of EBs dropped to less than 
70% in PRAS40 and less than 65% in TSC2 EBs (Figure 3.2.2) being in concordance 
with morphology observations. 
 
 
Figure 3.2.2 The number of EBs formed from the so transfected cells was counted on day 1 
and day 6 (day 1 control was set to 100%). 
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For differences in morphology and shape pictures were randomly taken with an Olympus 
microscope. With a software we were able to analyze the area of the differently siRNA 
treated EBs (Figure 3.2.4 and 3.2.5). For area analysis ten pictures were taken and area of 
the “inner area” of EBs and the “outer area” of EBs was measured. The term “inner area” 
comprises all the cells within the thin outline they are enclosed in. Annexed to this outline 
a layer of less compacted, brighter round shaped cells appear and are termed as “outer 
area”. The inner area and the outline of the outer area together are termed whole area of 
EBs in terms of the subsequently following results (Figure 3.2.3). Alone by observing the 
morphology of the EBs huge differences could be seen when control EBs where 
compared to PRAS40 and TSC2 siRNA treated EBs. 
 
Figure 3.2.3 The role of PRAS40 and tuberin in EB development of AFS cells. Left panel: 
representative pictures of day 1 EBs generated from differently transfected Q1 cells 
(magnification x10). Right panel: schematic presentation of the inner area of the EB (dark red) 
and the outer area (light red). For detailed explanation see the text. 
 
The outer area was a lot bigger in TSC2 treated EBs and it was even more in PRAS40 
EBs compared to control EBs (Figure 3.2.3). Analyzing the whole area of EBs at day 1 
there was not much difference within the differently treated EBs (Figure 3.2.4), fitting the 
morphological impression (Figure 3.2.3).  
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Figure 3.2.4 The whole area (outline of the outer area) of formed EBs was analysed at day 1. 
For each calculation 10 EBs were photographed, the area was analysed via Cell D image software 
(Olympus) and the data are presented as average ± standard deviation. 
 
In agreement with the morphological observation, the inner area of EBs was decreased in 
TSC2 EBs by approximately 40% and dramatically reduced by 60% in PRAS40 EBs 
(Figure 3.2.5). 
 
Figure 3.2.5 The inner area (outline of the inner area) of formed EBs was analysed at day 1. 
For each calculation 10 EBs were photographed, the area was analysed via Cell D image software 
(Olympus) and the data are presented as average ± standard deviation. For all statistical analyses 
Student`s t-tests (unpaired, two-tailed) were performed and * indicates statistical significance with 
a p-value ≤ 0,05. 
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To summarize the results obtained from morphological and area analysis we can conclude 
that the overall EB does not change in size, however due to the strong phenotypic 
differences we were able to show that PRAS40 and TSC2 EBs have a much smaller inner 
area of cells compared to control EBs.  
To get more insight into EB development we analyzed the cell number of EBs via a 
CASY cell counter and analyzer. 32 EBs were trypsinized to receive a single cell 
suspension and then measured with a CASY counter. Results of cell number analysis 
where quite similar in outcome compared with the area results. A dramatic loss in cell 
number (Figure 3.2.6) was observed in PRAS40 knockdown EBs (down to ~ 30%) and in 
TSC2 knockdown EBs (down to ~60%).  
 
 
Figure 3.2.6 The cell number of day 1 EBs (32 EBs for each calculation) was determined by a 
CASY cell counter and analyser and presented relative to the control. For all statistical analyses 
Student`s t-tests (unpaired, two-tailed) were performed and * indicates statistical significance with 
a p-value ≤ 0,05. 
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To further clarify the impact of PRAS40 and TSC2 knockdown in EBs we performed a 
short time course experiment. 12h and 24h post start of EB formation pictures were taken 
for morphological differences (Figure 3.2.7). Area analysis of 12h and 24h EBs was 
conducted. 
 
Figure 3.2.7 Representative pictures of 12 hours and 24 hours EBs formed from Q1 cells 
transfected as indicated (magnification x10). 
 
Already after 12h the area was significantly decreased in PRAS40 knockdown EBs and to 
a smaller but still significant extent in TSC2 knockdown EBs. 24h later, when analysis 
was usually performed, the impact on area was even greater, though an overall decrease 
in area was seen between 12h and 24h post EB formation, presumably resulting from the 
overall compaction of an EB during that time (Figure 3.2.8).  
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Figure 3.2.8 Area changes of EBs from differently transfected Q1 cells are time course 
dependent. The inner area of the EBs formed from transfected Q1 cells were analysed at the 
indicated time points. For each calculation 10 EBs were photographed, the area was analysed via 
Cell D image software (Olympus) and the data are presented as average ± standard deviation. For 
all statistical analyses Student`s t-tests (unpaired, two-tailed) were performed and * indicates 
statistical significance with a p-value ≤ 0,05. 
 
The decrease of the inner area and the massive drop in cell number needed further 
clarification. To get more insight into the cellular processes that occur during EB 
development we stained them with HOPI to check for possible apoptosis. 
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Figure 3.2.9 Knockdown of endogenous tuberin or PRAS40 triggers apoptosis during EB 
development of AFS cells. Day 1 EBs, from siRNA-treated Q1 cells as described in Fig. 3.2.1, 
were stained with HOPI for 1h at 37°C and then analysed on a confocal microscope 
(magnification x25). Scale bars represent 50µm. 
 
Using a confocal microscope we could see that the outgrowth is definitely positive for a 
HOPI double staining, providing strong evidence that knockdown of PRAS40 and TSC2 
in EBs leads to cell death (Figure 3.2.9). To further support the results rom HOPI that the 
outer area was mainly composed of dead cells and, that cells within the original area were 
viable, whole EBs were trypsinized to receive single cells for flow cytometry.  
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Figure 3.2.10 Whole EBs were trypsinized 24h post start of EB formation and relative cell size 
was studied via cytofluorometric forward scatter (FSC) analyses. 
 
Cell size (FSC) and subG1 cells were evaluated. Cell size was significantly larger in 
PRAS40 treated EBs and a slight trend could be observed in TSC2 EBs. The FSC overlay 
profile showed that cell shrinkage was present in PRAS40 EBs (Figure 3.2.10). PRAS40 
EBs had about three times more cells in the subG1 fraction and about 1,5 times more cells 
in TSC2 were in subG1 compared to control (Figure 3.2.11 A and B).  
We performed HOPI staining, which allows discriminating between necrosis, early and 
late apoptotis. For details of HOPI analysis see materials and methods section and 
publication by Grusch et al., (Grusch et al., 2002). Prior to the staining EBs were 
photographed for area analysis. In accordance to previous experiments, the area of 
PRAS40 treated EBs was significantly smaller compared to non treated or control siRNA 
treated EBs. TSC2 EBs also exhibited a significantly smaller area but to a less extent than 
PRAS40 EBs. Cells were treated as in previous experiments and 24h post EB formation 
cells were trypsinized to receive a single cell suspension. Cells were kept in media 
containing HOPI staining solution and were incubated for 1h at 37°C and 5% CO2 in an 
incubator. Afterwards cells were carefully resuspended and several drops of the 
suspension were put on a glass slide. Pictures of HOPI stained cells were taken (Figure 
3.2.12). 
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Figure 3.2.11 (A) In the same samples apoptotic cells were cytofluorometrically detected by 
their sub G1 DNA content. The log Q1 picture represents non-transfected Q1 control cells 
logarithmically growing in petri dishes without induction of EB formation. (B) Quantitative 
investigation of the amount of subG1 cells in EBs analysed in (C). Student’s t-test was performed 
and * indicate statistical significance (p-value ≤ 0,05; n=3 x 96 well plate). 
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Figure 3.2.12 Downregulation of endogenous tuberin or PRAS40 triggers apoptosis, but 
not necrosis, during EB formation of AFS cells. Day 1 EBs formed from Q1 cells, siRNA-
transfected as indicated, were trypsinized to receive single cells and stained with HOPI to monitor 
nuclear chromation condensation and cell death (arrows) (magnification x20).   
 
For the numerical analysis a minimum of 500 cells per condition were counted. First step 
of analysis was just to distinguish between living and apoptotic/necrotic cells. In both, 
non treated and control siRNA treated EBs, the percentage of living cells was above 80%. 
On the other hand PRAS40 and TSC2 EBs showed a reduction of living cells by 
approximately 15 to 20% compared to control and portion of apoptotic cells was above 
20% (Figure 3.2.13). The second step was to analyze all those cells, which were counted 
as either apoptotic/necrotic, by counting them as either early apoptotic (only positive for 
Hoechst dye – bright blue, smaller than living cells, apoptotic bodies), late apoptotic 
(positive for Hoechst dye and propidium iodide, looking purple, small nuclei and 
apoptotic bodies) and necrotic cells (positive for both dyes but swollen nuclei, no 
apopototic bodies). 
non treated control
PRAS40 TSC2
59 
 
 
Figure 3.2.13 Living and apoptotic/necrotic cells were counted upon HOPI staining and data are 
presented as average ± standard deviation (SD). Statistical analyses was performed via Student’s 
t-tests and * or ∆ indicate a p-value ≤ 0,05 compared with living control cells (*) or dead control 
cells (∆) (n≥ 500 cells per condition). 
 
Figure 3.2.14 Apoptotic/necrotic-positive cells were divided into apoptotic and necrotic cells 
(for details see materials and methods). 
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 Necrosis was never observed in a higher percentage than 8 percent. Therefore we were 
able to conclude that knockdown of PRAS40 and TSC2 did not trigger necrosis but 
definitely apoptosis. The differences of early and late apoptosis within one group were 
not statistically significant. Therefore we decided on just showing the difference between 
apoptotic and necrotic cell death in EBs to make clear that the phenotype is caused by 
programmed cell death (Figure 3.2.14). 
The conclusion so far is that knockdown of PRAS40 and TSC2 in EBs triggers apoptosis 
at a high level, leading to reduced area of EBs and a dramatic loss in cell number. This 
leads to the assumption that PRAS40 and TSC2 play key roles in the early development. 
To localize apoptosis we formed differently transfected EBs as previously described. First 
we shortly trypsinized EBs to get the outer cells of the EB and in a second step of 
trypsination we received single inner cells (for a more detailed description of separating 
inner and outer cells of EBs see the materials and methods section). Evaluating cell size 
of inner and outer cells of the EB via flow cytometric analysis releaved that cells treated 
with either PRAS40 or TSC2 siRNA within the inner area of an EB were bigger 
compared to control cells. This is in agreement with other studies on mTOR regulators as 
mTORC1 and mTORC2 are major regulators of cell size and cell cycle (Rosner et al., 
2009b). Vice versa cells out of the inner area of an EB were significantly smaller 
compared to control cells with PRAS40 siRNA treated cells being the smallest (Figure 
3.2.15 A and B). FSC overlays of cells inside (inner) and outside (outer) of the inner area 
of an EB clearly showed the size differences. Cell shrinkage was seen in PRAS40 and 
TSC2 siRNA treated EBs, whereas again the PRAS40 phenotype was stronger compared 
to TSC2 (Figure 3.2.15 A). To answer the question about where apoptosis is residing in 
the EB subG1 analysis was performed with cells inside (inner) and outside (outer) of the 
EB. The level and grade of subG1 cells of differently treated EBs could nicely be spotted 
in DNA profiles depicted (Figure 3.2.15 C). We could demonstrate that the cells inside 
approximately have the same level of subG1 cells, whereas there were tremendous 
differences in cells outside. Almost 60% of all the cells of the outer area were in subG1 in 
PRAS40 EBs and up to 40% of those cells were in subG1 in TSC2 EBs (Figure 3.2.15 D).  
 
 
61
 
 
 
A
)
B
)
C
)
in
ne
r
ou
te
r
D
)
in
ne
r
ou
te
r
counts counts
F
S
C
counts
2N
4N
2N
4N
2N
4N
co
nt
ro
l
P
R
A
S
40
TS
C
2
2N
4N
2N
4N
2N
4N
counts
D
N
A
 c
on
te
nt
co
nt
ro
l
P
R
A
S
40
TS
C
2
10
0
20
0
30
0
40
0
in
ne
r
ou
te
r
FSC mean
*
*
co
nt
ro
l
P
R
A
S
40
TS
C
2
co
nt
ro
l
P
R
A
S
40
TS
C
2
0204060
in
ne
r
ou
te
r
subG1 (%)
Fi
gu
re
 3
.2
.1
5 
T
he
 o
ut
er
 a
re
a 
of
 
A
FS
 
ce
ll 
E
B
s 
re
pr
es
en
ts
 
ap
op
to
si
s 
in
du
ce
d 
by
 t
ub
er
in
 o
r 
PR
A
S4
0 
kn
oc
kd
ow
n.
 (
A
) 
D
ay
 1
 
EB
s 
of
 c
on
tro
l, 
PR
A
S4
0 
or
 T
SC
2 
si
R
N
A
-tr
an
sf
ec
te
d 
Q
1 
ce
lls
 w
er
e 
fir
st
 s
ho
rtl
y 
try
ps
in
iz
ed
 t
o 
ha
rv
es
t 
th
e 
ou
te
r c
el
ls
 a
nd
 in
 a
 s
ec
on
d 
st
ep
 
fo
r t
he
 in
ne
r E
B
 c
el
ls
 (f
or
 th
e 
ex
ac
t 
ce
ll 
se
pa
ra
tio
n 
pr
oc
ed
ur
e 
se
e 
m
at
er
ia
ls
 a
nd
 m
et
ho
ds
). 
C
el
l 
si
ze
 
(c
el
l 
sh
rin
ka
ge
 
re
pr
es
en
ts
 
de
ad
 
ce
lls
) 
w
as
 
cy
to
flu
or
om
et
ric
al
ly
 
in
ve
st
ig
at
ed
 
by
 
fo
rw
ar
d 
sc
at
te
r 
an
al
ys
is
. 
(B
) 
C
om
pa
ris
on
 o
f 
th
e 
re
la
tiv
e 
ce
ll 
si
ze
 (
FS
C
 m
ea
n)
 o
f 
in
ne
r 
an
d 
ou
te
r 
ce
lls
 i
n 
di
ff
er
en
tly
 
si
R
N
A
-tr
an
sf
ec
te
d 
EB
s 
(p
-v
al
ue
 ≤ 
0,
05
; S
tu
de
nt
’s
 t-
te
st
 n
=3
x 
96
 w
el
l 
pl
at
e)
. 
(C
) 
C
yt
of
lu
or
om
et
ric
al
 
an
al
ys
is
 o
f t
he
 a
m
ou
nt
 o
f a
po
pt
ot
ic
 
su
bG
1 
ce
lls
 w
ith
 f
ra
gm
en
te
d 
D
N
A
 
w
ith
in
 th
e 
in
ne
r 
an
d 
th
e 
ou
te
r 
ar
ea
 
of
 E
B
s 
fr
om
 c
on
tro
l, 
PR
A
S4
0 
or
 
TS
C
2-
si
R
N
A
 t
ra
ns
fe
ct
ed
 Q
1 
ce
lls
. 
(D
) 
A
na
ly
si
s 
of
 t
he
 p
er
ce
nt
ag
e 
of
 
su
bG
1 
ce
lls
 w
ith
in
 t
he
 i
nn
er
 a
nd
 
ou
te
r 
ar
ea
s 
of
 
di
ff
er
en
tly
 
tra
ns
fe
ct
ed
 E
B
s 
(P
-v
al
ue
 ≤
 0
,0
5;
 
St
ud
en
t’s
 
t-t
es
t 
n=
3x
 
96
-W
el
l-
Pl
at
e)
. 
62 
 
We next wanted to assess whether the knockdown of PRAS40 and TSC2 was 
accompanied with changes in germ layer expression caused by the knockdowns. We 
choose the following markers for analysis: αFP (alphafetoprotein) as an endodermal 
marker, nestin as an ectodermal marker, WT1 (Wilms tumor 1) mesodermal marker. 
αFP is a glycoprotein, which is usually only expressed in the fetus and expression 
decreases after birth. It is regulated by p53 and ß-catenin and found in elevated levels in 
adult liver cancer cells (Meier et al., 2006; Peng et al., 2004; Warnes and Smith, 1987). In 
stem cell biology αFP is used as a marker for endoderm, especially the primitive 
endoderm. Nestin is a family member of the intermediate filament group and structurally 
related to the neurofilament proteins. It is highly expressed in the developing brain and 
other neuronal structures. Nestin is widely used as ectodermal, neuronal and pancreatic 
progenitor marker of stem cells (Gilyarov, 2008; Messam et al., 2002; Wang et al., 2009). 
WT-1 is a zinc-finger transcription factor and involved in Wilms’ tumor, a renal 
malignancy in infants and a known regulator of kidney development. It is strongly 
expressed in mesenchymal derived tissue (Davies et al., 2004; Pritchard-Jones et al., 
1990). All of the markers tested were expressed in Q1 cells and the germ layer maker 
WT-1 was approved as previously published (Siegel et al., 2010). In addition to the 
stainings performed in Q1, we had to prove specificity of the antibodies. Cell lines 
positive and negative for the markers were used to do so (Figure 3.2.16). 
EBs were generated and fixed in 4% PFA at day 1 and incubated with the following 
primary antibodies: αFP (endoderm), nestin (ectoderm) and WT1 (mesoderm). EBs were 
counterstained with DAPI for nuclei staining and embedded onto a glass slide. EBs were 
analyzed on a confocal microscope. Although we monitored a reduced in size of the inner 
EB in PRAS40 and TSC2 knockdown EBs, marker specific stainings did not show any 
difference between control and knockdown EBs (Figure 3.2.17). We conclude that 
knockdown of PRAS40 and TSC2 in EBs is not deregulating germ layer marker 
expression.  
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Figure 3.2.16  Analyses of control cells to prove antibody specificity. (A) Staining for
αFP with IMR-90 cells serving as negative control and Hela cells as positive control. Top row
represents staining with primary antibody and bottom row represents negative control staining
omitting the primary antibody. Scale bars represent 100µm. (B) Staining for nestin with Jurkat
T cells serving as negative control and SK-N-SH cells as positive control. Top row represents
staining with primary antibody and bottom row represents negative control staining omitting the
primary antibody. Scale bars represent 100µm. (C) Staining for WT-1 with MCF-7 cells serving
as negative control and mouse embryonic kidney (E11,5) as positive control. Top row
represents staining with primary antibody and bottom row represents negative control staining
omitting the primary antibody. Scale bars for MCF-7 represent 100µm and for embryonic
kidney 50µm. 
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Figure 3.2.17 Knockdown of endogenous tuberin or PRAS40 is not affecting germ layer 
specific marker expression. Monoclonal Q1 AFS cells were transfected with non-targeting 
control, PRAS40- or TSC2-specific siRNA. Day 1 EBs were immunohistochemically analysed  
for marker expression (WT1-mesoderm; FP-endoderm; Nestin-ectoderm). Nuclei were 
counterstained with DAPI in blue (magnification x25). Scale bars represent 20 µm. 
 
To briefly summarize the results obtained so far we could definitely prove that firstly, 
PRAS40 and TSC2 are genes essential in early development. Secondly, that these genes 
do regulate apoptosis in embryoid body development. Thirdly, that knockdown of these 
genes severely affects area and cell number however not having an impact of the germ 
layer markers investigated in this study.  
 
The next step was to identify the molecular mechanism by which knockdown of PRAS40 
and TSC2 regulate apoptosis. As PRAS40 and TSC2 are both prominent inhibitors of the 
mTORC1 signaling pathway (Dunlop and Tee, 2009; Inoki et al., 2002; Nascimento and 
Ouwens, 2009; Rosner et al., 2008a; Sancak et al., 2007; Tee et al., 2003) it was quite 
self-evident to test whether regulating mTORC1 could revert the phenotype observed in 
PRAS40 and TSC2 siRNA treated EBs. One of the best ways to efficiently block the 
mTORC1 signaling cascade is the chemical inhibitor rapamycin. Q1 cells were 
transfected with control, PRAS40 or TSC2 siRNA, then grown for 48h. Then cells were 
treated with 100nM rapamycin or DMSO and grown for another 24h (in total 72h as 
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usual). For EB formation cells were additionally treated with rapamycin or vehicle control 
(DMSO) and analysis was performed 24h later (Figure 3.2.18).  
 
 
Figure 3.2.18 Scheme of experimental approach of siRNA knockdown and rapamycin treatment 
of Q1 hAFS cells and EB formation. 
 
For confirmation that rapamycin indeed blocked mTORC1 Western blot analysis was 
performed from cell lysates of Q1 used for EB formation. Efficient knockdown of 
PRAS40 and TSC2 was confirmed.  
 
Figure 3.2.19 Q1 AFS cells were transfected with non-targeting control siRNA, PRAS40 
siRNA or TSC2 siRNA. 48h after transfection cells were treated with 100nM Rapamycin or 
vehicle (DMSO). Efficient knockdown of PRAS40 or TSC2 protein was confirmed by Western 
blot analysis 72 hours after transfection. Additionally, the negative effects of rapamycin on 
mTORC1 activity were confirmed by analyzing the phosphorylation status of p70S6K T389. 
GAPDH served as a control for equal loading. 
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The readouts of mTORC1 activity p70S6K was analyzed. Phosphorylation of p70S6K at 
T389 was completely blocked by rapamycin and in total p70S6K protein a shift towards 
the dephosphorylated state was detectable (Figure 3.2.19). Phosphorylation at S240/244 
of S6 was quite effectively blocked and in addition to mTORC1 direct read out we could 
show that phosphorylation of AKT at S473 was slightly induced by rapamycin, triggered 
via the negative feedback loop of p70S6K towards IRS and then AKT (Dunlop and Tee, 
2009; Rosner and Hengstschlager, 2008). GAPDH served as a control for equal loading. 
As one of the most prominent features in these EBs was the dramatic phenotype, we 
analyzed the inner and the whole area of the differently treated EBs. As expected siRNA 
treated cells together with DMSO did exhibit the usually observed phenotype. Rapamycin 
could not revert the effects of PRAS40 and TSC2 knockdown EBs it even led to a further 
decrease of the inner area of siRNA treated EBs compared to control (Figure 3.2.20).  
 
 
Figure 3.2.20 Knockdown of tuberin or PRAS40 also causes apoptosis in AFS cell EBs 
treated with the mTOR inhibitor rapamycin. The inner area (outline of the inner area) of 
formed day 1 EBs was analysed. For each calculation 10 EBs were photographed, the area was 
analysed via Cell D image software (Olympus) and the data are presented as average ± standard 
deviation (control set to 100%). 
 
When evaluating the cell number of differently transfected EBs treated with or without 
rapamycin we could prove for another time that cell number dramatically dropped by 
about 50% in PRAS40 treated EBs and item by 20% in TSC2 EBs.  
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Figure 3.2.21 The cell number of these EBs (32 EBs for each calculation) was determined by a 
CASY cell counter and analyser. For all statistical analyses in this figure Student`s t-tests 
(unpaired, two-tailed) were performed and * indicates statistical significance with a p-value ≤ 
0,05. 
 
What has already become evident when analyzing the original area of the EBs, moreover 
at a concentration of 100nM, rapamycin was not capable of rescuing the loss of cells due 
to apoptosis in EBs treated with PRAS40 or TSC2 siRNA (Figure 3.2.21). 
Based on the results obtained from analyzing the EBs and from Western blot analysis we 
can state that rapamycin was not able to compensate the apoptotic phenotype resulting 
from PRAS40 and TSC2 knockdown in EBs. 
 
The mTOR protein is present in two different protein complexes, namely mTORC1 and 
mTORC2, and rapamycin primarily targets mTORC1. In addition there’s evidence that 
TSC2 influences mTORC2 activity (Huang et al., 2008). For that reason and to rule out 
any doubt about how PRAS40 and TSC2 are regulated in this system (mTOR dependent 
or independent), we performed double knockdowns with additional mTOR or non-
targeting control siRNA in Q1 hAFS cells using 25nM of each siRNA to transfect, 
resulting in a total of 50nM, and used those cells 72h post siRNA transfection for EB 
formation.  
To confirm that mTOR was indeed knocked down in Q1 cells used for EB formation and 
that due to that the downstream signaling was affected Western blot analysis was 
0
20
40
60
80
100
120
ce
ll 
nu
m
be
r
(%
)
*
0
20
40
60
80
100
120
ce
ll 
nu
m
be
r
(%
)
*
68 
 
performed. Although using only half of the amount of siRNA as usual all knockdowns 
could be verified (PRAS40, TSC2 and mTOR). Deregulating mTOR resulted in a 
decrease in p70S6K phosphorylation at T389 and consequently a reduced 
phosphorylation of ribosomal protein S6 at S240/244 (data not shown). Double 
knockdown of mTOR and PRAS40 or TSC2 could partly revert the effect of the mTOR 
knockdown (Figure 3.2.22). 
More important to us was the difference in the original area of the EBs providing 
information about cell / EB viability and phenotype to us. EBs treated with control, 
PRAS40 and TSC2 siRNA and additionally transfected with non targeting control siRNA 
showed the same phenotype as observed in previous experiments.  
 
Figure 3.2.22 Q1 AFS cells were transfected with non-targeting control siRNA, PRAS40 
siRNA or TSC2 siRNA and co-transfected with either control or mTOR-specific siRNA. 
Knockdown of endogenous PRAS40, TSC2 or mTOR protein was confirmed by Western blot 
analysis 72 hours after transfection. Additionally, the mTORC1-dependent phosphorylation status 
of p70S6K T389 was analysed. A non-specific band served as a control for equal loading. 
 
This goes hand in hand with the area measurements with a significant decrease in TSC2 
knockdown EBs and an even higher decrease in area in PRAS40 EBs (Figure 3.2.23). 
EBs, where mTOR was knocked down, were significantly smaller than control EBs, being 
consistent with our previously published data, where raptor and rictor knockdown clearly 
reduced area of EBs (Valli et al., 2010). 
α- PRAS40
α- tuberin
α- mTOR
α- p70S6K T389
NB
control mTOR
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Figure 3.2.23 The apoptotic effects of tuberin or PRAS40 knockdown depend on mTOR. 
The inner area (outline of the inner area) of formed day 1 EBs was analysed. For each calculation 
10 EBs were photographed, the area was analysed via Cell D image software (Olympus) and the 
data are presented as average ± standard deviation (control set to 100%). 
 
From phenotype observation and quantification of the inner area of the EBs we could 
show that additional knockdown of mTOR was able to compensate the effects of PRAS40 
and TSC2 knockdown EBs (Figure 3.2.23). 
Analysis of cell number data confirmed again the increased cell death resulting from 
PRAS40 and TSC2 knockdown in EBs. However when comparing differently transfected 
EBs additionally treated with mTOR siRNA, we observed a much smaller loss of cells in 
PRAS40 siRNA treated EBs and TSC2 siRNA treated EBs and moreover decreases were 
not statistically significant (Figure 3.2.24). 
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Figure 3.2.24 The cell number of these EBs (32 EBs for each calculation) was determined by a 
CASY cell counter and analyser. For all statistical analyses in this figure Student`s t-tests 
(unpaired, two-tailed) were performed and * indicates statistical significance with a p-value ≤ 
0,05. 
 
From the results obtained in these experiments we found that mTOR can efficiently 
compensate the phenotype of PRAS40 and TSC2 knockdown EBs and that PRAS40 and 
TSC2 regulate EB development via mTOR. 
Summing up all the results from this study we conclude that firstly, PRAS40 and TSC2 
are major anti-apoptotic gatekeepers in early development and secondly this regulation 
depends on rapamycin- insensitive functions of mTOR. 
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4. DISCUSSION 
4.1 The localization of PRAS40 
PRAS40 was identified as a new substrate for AKT in 2003 (Kovacina et al., 2003), 
bound by 14-3-3 when phosphorylated on Thr246. Later it was shown that PRAS40 is an 
inhibitor of mTORC1 until phosphorylated at Thr246 (Sancak et al., 2007; Vander Haar 
et al., 2007). Furthermore it was found that PRAS40 is part of the mTORC1 complex, 
acting as an direct inhibitor for substrate binding (Fonseca et al., 2007; Oshiro et al., 
2007; Wang et al., 2008; Wang et al., 2007).  
Here we show for the first time, that it is primarily a cytoplasmic protein in 
logarithmically growing human fetal lung fibroblasts IMR-90. We could also show that 
the localization is the same in Hek293 cells. Our results fit very well to the localization of 
other AKT substrates e.g. tuberin (Rosner et al., 2007a) and the localization of mTORC1 
(Rosner and Hengstschlager, 2008). From the two mTOR complexes, mTOR itself, rictor, 
sin1 and mLST8 are predominantly cytoplasmic, only raptor can be found equally 
distributed in the cytoplasm and the nucleus. However the assembly of mTORC1 occurs 
predominantly in the cytoplasm (Rosner and Hengstschlager, 2008). Therefore it makes 
sense that PRAS40, as a substrate / component of mTORC1 is primarily found in the 
cytoplasm to conduct its regulatory function. Multiple other regulators or substrates of 
mTORC1 signalling e.g. PI3K, AKT and S6K1 are found in both compartments (Furuya 
et al., 2006; Kim and Chen, 2000; Panasyuk et al., 2006; Saji et al., 2005). PRAS40 
posses an NES (nuclear export sequence) in its C-terminal region suggesting that 
PRAS40 can shuttle between the nucleus and the cytoplasm (Nascimento and Ouwens, 
2009). Some studies reported that PRAS40 is localized to the nucleus. One group reported 
that in A14 fibroblasts and E2 H9c2 cardiomyocytes gave nuclear phospho-PRAS40 
Thr246 staining promoted by insulin (Nascimento et al., 2006). However one has to 
mention that A14 fibroblasts are NIH3T3 cells overexpressing the human insulin receptor 
and the same is true for E2 H9c2 cardiomyocytes. Besides as negative controls are 
missing one has to critically look at the localization of PRAS40 under basal conditions if 
this staining is really specific. Another group showed that phospho-PRAS40 colocalized 
with neuron-specific nuclear protein (NeuN) 24 hours after transient focal cerebral 
ischemia (Saito et al., 2004). Injection of insulin into rats gave nuclear phospho-PRAS40 
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staining of rat liver and cardiac ventricular tissue sections (Nascimento et al., 2006). One 
has to keep in mind that most of these experiments were carried out via stimulation or 
treatment and did not investigate normal basal conditions. Additionally it could be that 
PRAS40 when strongly phosphorylated by AKT (on Thr246), mTORC1 (on Ser183), 
PIM-1 (on Thr246) or other currently unknown regulators changes it localization from 
cytoplasm to the nucleus in is phosphorylated state to conduct e.g. anti-apoptotic (Saito et 
al., 2006; Saito et al., 2004) or other regulatory functions in the nucleus. Yet this is a 
subject to clarify. 
As PRAS40 is targeted by AKT and phosphorylated by it, we further investigated the role 
of AKT on PRAS40 localization. In previous studies it has been shown that 
phosphorylation by AKT can regulate a protein’s localization e.g. nuclear and 
cytoplasmic localization of p27 (Fujita et al., 2002; Liang et al., 2002; Shin et al., 2002; 
Viglietto et al., 2002). As already mentioned above tuberin is mainly localized to the 
cytoplasm, however its nuclear proportion can be localized to the cytoplasm via active 
AKT (Rosner et al., 2007a). AKT protein itself is almost exclusively localized to the 
cytoplasm and to obtain AKT bands of a nuclear fraction on a Western blot requires long 
exposure times (Rosner et al., 2007b). However from the obtained results, although it 
seems AKT-mediated phosphorylation of PRAS40 on Thr246 does not affect PRAS40 
localization, we still cannot rule out a role for AKT in PRAS40 localization and 
experiments simply overexpressing constitutive active AKT in IMR-90 and further 
nuclear and cytplasmic fractionation should give more insight into PRAS40 localization 
and its regulation.  
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4.2 PRAS40 and TSC2 regulate apoptosis during early development of 
embryoid bodies via mTOR 
Amniotic fluid stem cells are an important source for both basic science and regenerative 
medicine. Besides of being pluripotent (Pappa and Anagnou, 2009) and highly 
proliferating cells, they do not raise the ethical concerns human ES cells are accompanied 
with and have a much higher potential compared to adult stem cells. Secondly hAFS cells 
do not produce teratomas in SCID mice when transplanted, which is a major concern in 
ES cells (Cananzi et al., 2009; Perin et al., 2008; Siegel et al., 2008; Siegel et al., 2007; 
Trounson, 2007). Moreover these stem cells can be a useful tool to generate disease 
specific stem cell lines, which would be optimal biological model systems to recapitulate 
normal and pathogenic differentiation in vitro (Valli et al., 2010). This has already been 
demonstrated to be functional using iPS cells from patients with various diseases (Dimos 
et al., 2008; Maherali and Hochedlinger, 2008; Park et al., 2008). In the past years our 
group was able to provide new and essential data on hAFS cells, 1) that the mTOR 
signaling pathway is functional in hAFS cells (Siegel et al., 2009), 2) that hAFS cells 
have the ability to form EBs and that the mTOR pathway plays a critical role in EB 
development (Valli et al., 2010) and 3) hAFS cells harbor the potential to integrate and 
even induce the expression of specific renal markers (Siegel et al., 2010). 
The main aim of this thesis was to elucidate the roles of PRAS40 and TSC2, two major 
regulators of the mTOR signaling pathway, in early embryonic development using hAFS 
cell derived EBs. EBs served as well recognized in vitro differentiation and early 
developmental model. We used siRNA to knockdown our genes of interest, as we have 
reported previously that this could be efficiently achieved in hAFS cells (Rosner et al., 
2010; Siegel et al., 2010) and that stability of knockdowns could be maintained for 
several days, even up to two weeks (Rosner et al., 2010). 
The mTOR pathway plays a major role in development demonstrated through knockout 
mice of e.g. mTOR, raptor, rictor and mLST8, which are components of the two mTOR 
complexes. mTOR-/- mice were embryonic lethal by E11.5 to E 12.5 (Gangloff et al., 
2004; Murakami et al., 2004) proving mTOR to be indispensible during embryonic 
development. Homozygous embryos showed growth arrest, although they could implant, 
as they were delayed in development and could not advance beyond E5.5. Furthermore at 
E5.5 developmental patterning was abnormal resulting in disorganization with no clear 
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extraembryonic or embryonic boundaries (Gangloff et al., 2004). Another study puts 
embryonic lethality for mTOR-/- mice already at embryonic stage E6.5 - 7.5 due to 
impaired cell proliferation of ICM and trophoblasts (Murakami et al., 2004). In addition 
they also compared the effect of rapamycin with the mTOR deletion. Concerning the 
trophoblast outgrowth rapamycin did mimick the mTOR-/- effect; however rapamycin was 
unable to impair ICM proliferation (Murakami et al., 2004). Therefore it is suggested that 
the effect of mTOR deletion is stronger than that of rapamycin. Studies on rapamycin by 
other groups showed that injection of rapamycin from E5.5 to 8.5 resulted in decreased 
proliferation of the telencephalic primordium, though most of the embryo developed 
normally (Hentges et al., 2001). In ES cells rapamycin did not block proliferation but 
rather slowed it down (Jirmanova et al., 2002; Kawasome et al., 1998; Murakami et al., 
2004). It was postulated that mTOR is not essential in mouse embryos and ES cells 
(Jirmanova et al., 2002; Kawasome et al., 1998), however this contradicts the results of 
Murakami et al. Their explanation is the existence of a rapamycin-insensitive function for 
mTOR. This is in perfect agreement with the results obtained in this study as rapamycin 
was not able to revert the apoptotic effects in PRAS40 and TSC2 knockdown EBs, but 
knockdown of mTOR was.  
Later components of both mTOR complexes were knocked out displaying different onsets 
of abnormal development and embryonic lethality. Raptor-/- mice exhibited defects in 
ICM and trophoblast cell outgrowth and stopped growth by day 4. By day 7 most of the 
embryos died and appeared as disorganized apoptotic-like bodies (Guertin et al., 2006). 
mLST8-/- did not show proliferation defects at the time point mTOR or raptor null 
embryos did, yet at about midgestation mLST8-/- embryos died at E10.5. Most evident in 
those null embryos was a failure of development of the cephalic region in comparison to 
wild type embryos despite no change in apoptosis or cell cycling rates (Guertin et al., 
2006). As the mLST8-/- embryos did not exhibit the same severe phenotype as raptor-/- 
and mTOR-/- it was suggested by Guertin et al., that mLST8 is not required for mTORC1 
complex formation and proper function in development. Therefore they studied the 
phenotype of rictor-/- embryos and showed that those feature very similar characteristics 
as the mLST8-/- embryo. Both null embryos presumably die from defective vascular 
development (Guertin et al., 2006). In another publication embryos lacking rictor 
developed normal until E9.5, followed by growth arrest and death by E11.5 (Shiota et al., 
2006). Although no disturbances were seen in gross structure, at the cellular level 
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hydropic changes occurred, which was evident by nuclear swelling and formation of 
vacuoles seen in neural epithelial cells, cardiac myocytes, endothelial and mesenchymal 
cells (Shiota et al., 2006). Shiota et al., suggested that rictor knockout prevents assembly 
of mTORC2 and that the embryonic lethal phenotype is at least partially due to defects in 
AKT/PKB signaling.  
The negative mTOR regulator TSC2 is also indispensible in early development. TSC2 
null embryos died at E9.5 – E12.5 from hepatic hypoplasia (Onda et al., 1999). These 
embryos were overall smaller and the liver was markedly hypoplastic with dilated 
sinusoids. Viable embryos at E8.0 – E12.5 were less developed with a delay of 
approximately 1-2 days. Additionally TSC2-/- embryos were paler and often had 
pericardial effusions. By E9.0 – E12.5 poor development of other abdominal organs and 
an abnormal heart size that was shifted inferiorly appeared. The main cause of death in 
TSC2-/- embryos was due to liver hypoplasia with secondary growth retardation and 
circulatory failure from anemia (Onda et al., 1999). In another study authors put 
embryonic lethality of TSC2 null embryos at about E10.5, but some dead or resorbed 
embryos were already present at E9.0 – E9.5 and some survived even till E12.5 
(Kobayashi et al., 1999) indicating a variability in lethal stage. The most prominent 
phenotypes were the non closure of the neural tube in the head region and an abnormal 
mycocardium with increased cell density (Kobayashi et al., 1999). 
For PRAS40, the other regulator of mTORC1 investigated in this study, no knockout 
mice exist to date and therefore no information about its role in embryonic development. 
Table 4.2.1 provides a summary of the above described phenotypes of the different 
knockout mice. 
It is more than evident that the mTOR signaling pathway is indispensible in embryonic 
development; however these data were obtained from mice and so far little data exist for 
human development. In 2009 a paper was published that revealed that mTOR signaling is 
needed for proper self-renewal in human ES cells and that impaired mTOR signaling led 
to differentiation of hES cells and triggered mesoderm and endoderm expression (Zhou et 
al., 2009). In 2010, for the first time, our group published that hAFS cells are able to form 
EBs and that the formation of EBs and their differentiation was highly dependent on 
mTOR (Valli et al., 2010). In this study we show for the first time that two of the major 
regulators of mTOR, namely PRAS40 and TSC2, are essential in human embryonic 
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development as they are anti-apoptotic gatekeepers in EB development. At day 1 the EB 
formation was approximately the same in PRAS40 and TSC2 silenced EBs as in control 
EBs. Later on , with an onset at about day 3 to day 4, the stability of those EBs was 
affected by the knockdowns and dramatically dropped to 65 – 70 % in silenced EBs. This 
provides strong evidence for the necessity of PRAS40 and TSC2 during early 
development. A major change in morphology of EBs was evident already 12h post start of 
EB formation as PRAS40 and TSC2 EBs displayed a defined inner and outer area of 
cells. The analysis of the inner area of EBs revealed a drastic and significant decrease in 
area in PRAS40 (ranging from ~ 50 – 65 %) and TSC2 (ranging from ~ 60 – 80 %) 
silenced EBs. Very similar outcome was gained by investigating the cell number of EBs, 
where PRAS40 and TSC2 knockdown EBs exhibited fewer living cells. Examining the 
morphology and area of silenced PRAS40 and TSC2 EBs already 12h post start of EB 
formation, indicated that the PRAS40 phenotype is being displayed earlier than the TSC2 
phenotype and additionally seemed to be more severe.  
Knockdown of PRAS40 and TSC2 triggered apoptosis in hAFS cell derived EBs. Both 
proteins are found to be involved in regulating cell survival and apoptosis as they are part 
of one major cell survival pathway the PI3K/AKT/mTOR signaling pathway. Most 
studies on PRAS40 and apoptosis were done using different model/tissue systems e.g. 
spinal cord injury, stroke and cancers. In the area peripheral to the lesion after spinal cord 
injury, increased expression of phospho-PRAS40 was observed. The increase of phospho-
PRAS40 markedly decreased motor neuron death and vice versa downregulation of 
phospho-PRAS40 increased apoptotic death after spinal cord injury (Yu et al., 2008). 
PRAS40’s neuroprotective role was investigated in transient focal cerebral ischemia 
(tFCI). Overexpression of phospho-PRAS40 in neurons attenuated apoptotic neuronal cell 
death after tFCI and furthermore treatment with NGF promoted phospho-PRAS40 
expression (Saito et al., 2004). The phosphorylation of PRAS40 and the induced 
anchoring to 14-3-3 might prevent progression towards apoptosis. Therefore it was 
suggested that PRAS40 might play a critical role in the survival pathway and should be 
considered as a therapeutic target for stroke (Saito et al., 2004). PRAS40 also seems to be 
a regulator of cell survival in cancer as phosphorylation of PRAS40 on T246 was 
increased in various pre-malignant and malignant lung and breast cancer cell lines. Their 
conclusion was that the PI3K-AKT pathway is the main pathway PRAS40 is contributing 
to cell survival (Huang and Porter, 2005). In malignant melanoma PRAS40 deregulates 
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apoptosis and promotes chemoresistance to apoptosis inducing agents, providing evidence 
that active PRAS40 gives a selective survival advantage in tumor environment 
(Madhunapantula et al., 2007). 
Conversely to the studies of Yu et al., and Saito et al., downregulation of PRAS40 
expression protected against the induction of apoptosis by TNFα or cycloheximide 
(Thedieck et al., 2007). In their study rapamycin failed to mimic the proapoptotic effect of 
PRAS40 knockdown and authors suggested that apoptosis was regulated independently of 
rapamycin-sensitive mTORC1 by PRAS40 (Thedieck et al., 2007). Yet the role of 
mTORC1 signaling on PRAS40 in apoptosis has not been determined in other studies. 
Given the observed differences of the impact of PRAS40 silencing on mTORC1 (Fonseca 
et al., 2007; Oshiro et al., 2007; Vander Haar et al., 2007; Wang et al., 2007; Zhang et al., 
2009) further studies are definitely required to elucidate the role of mTORC1 on the 
regulation of apoptosis via PRAS40 (Nascimento and Ouwens, 2009). This thesis 
provides new insight into how PRAS40 regulates apoptosis in early development using a 
human in vitro developmental system. In the here presented study we could show that 
silencing PRAS40 in EBs derived from hAFS cells triggered massive apoptosis. Using 
different methods for the measurement e.g. HOPI, subG1 and cell shrinkage via flow 
cytometry, of cell death we could determine that 1) cell death is increased by 
approximately 2 to 3 fold in PRAS40 knockdown EBs, 2) cell death is due to apoptosis 
and not necrosis as determined by HOPI and 3) that the outer area is mainly apoptotic 
shown through cell shrinkage and subG1 and that there is no difference in subG1 of the 
inner cells compared to control EBs. TSC2 silenced EBs were also inducing apoptosis in 
EBs derived from hAFS cells thus to a lesser extent PRAS40 knockdown did. As 
PRAS40 is linked to apoptosis TSC2 is as well, for example TSC2 overexpressing 3T3 
cells were prone to apoptosis (Pasumarthi et al., 2000). In another study high levels of 
tuberin triggered apoptosis which was accompanied by p70S6K inactivation, 
downregulation of phospho-BAD S136 and the upregulation of BAD and BCL-2/BCL-XL 
interaction (Freilinger et al., 2006b). 
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As TSC2 is regulating apopotosis via mTOR and p70S6K mediating BAD 
phosphorylation, it was suggested that cells lacking functional TSC2 are better protected 
against apoptotic stimuli and resemble the TSC tumor model (Freilinger et al., 2006b). 
Figure 4.2.1 represents the signaling pathway TSC2 is involved in to activate the 
proapoptotic molecule BAD. 
 
Figure 4.2.1 Tuberin’s effects to control p70S6K activity, BAD phosphorylation, BAD/BCL-2 
and BAD/BCL-XL complex formation and apoptosis are negatively regulated by AKT (Freilinger 
et al., 2006b). 
 
In the same year it was also published that TSC2 negatively affects BCL-2’s cell survival 
function, but still it was suggested that tuberin might fulfill different functions in 
apoptosis depending on the exogenous signals (Freilinger et al., 2006a). 
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Cell survival via regulating tuberin can also be achieved via Ras signaling pathway, as it 
negatively regulates tuberin-induced apoptosis. It was shown that activated Ras was able 
to downregulate tuberin’s potential to block p70S6K activity (Freilinger et al., 2008). In 
this report authors mention for the first time a functional connection between oncogenic 
Ras and the tumor suppressor protein tuberin. Therefore they suggested that activation of 
tuberin might be a useful therapeutic intervention concept in cancers, where Ras is 
mutated (Freilinger et al., 2008). Figure 4.2.2 views the suggested signaling pathway on 
how Ras mediates cell survival signals by regulating tuberin. 
 
Figure 4.2.2 Suggested pathway for Ras-induced cell survival via regulating tuberin. Ras-
mediated cell survival is accompanied by upregulation of extracellular signal-regulated kinase 
(ERK) activity, but not of AKT activity. 
 
TSC2 silenced EBs also showed increased susceptibility to apoptosis like PRAS40 
silenced EBs but to a much lesser extent, which was already obvious in area and cell 
number analysis. However, HOPI and flow cytometric analysis also revealed that TSC2 
knockdown in EBs is definitely leading to apoptosis and not necrosis, that cell shrinkage 
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is taking place and that the outer cells of EBs were apoptotic and no visible difference in 
cell viability was seen in inner cells when compared to control EBs.  
Taking together the so far obtained data we can say that PRAS40 and TSC2 are major 
anti-apoptotic gatekeepers during early embryonic development. Therefore deregulation 
of any one of the two triggers apoptosis and it is plausible that severe developmental 
effects would occur in vivo.  
As the knockdown of PRAS40 and TSC2 in EBs triggered apoptosis and this could have 
caused deregulation of the germ layers, we stained differently treated EBs with markers 
for mesoderm (WT1), endoderm (αFP) and ectoderm (nestin). Although the change in the 
overall EB size was evident through DAPI staining, no significant change in germ layer 
marker expression was visible in PRAS40 and TSC2 knockdown EBs. Therefore we 
suggest that PRAS40 and TSC2 are not major regulators of germ layer differentiation and 
are more important for regulation of cell survival or maybe even homeostasis. Still as we 
analyzed only three markers it could be possible that those two genes play some role in 
differentiation of the three germ layers. 
PRAS40 and TSC2 are potent negative regulators of mTORC1 (Dunlop and Tee, 2009; 
Hall, 2008; Rosner et al., 2008a) and mTOR signaling pathway seems to play an essential 
role during embryogenesis (Guertin et al., 2006; Murakami et al., 2004; Zhou et al., 
2009). Using the chemical inhibitor of mTORC1 – rapamycin – we tried to revert the 
knockdown effects; however we were unable to do so. From Western blot analysis we 
were able to confirm knockdown of our genes of interest and 100nM rapamycin 
specifically blocked mTORC1 kinase activity towards p70S6K, which was evident 
through ablation of T389 phosphorylation of p70S6K. Yet the decrease in area and cell 
number in PRAS40 and TSC2 knockdown EBs could not be reverted by the addition of 
rapamycin. Surprisingly, adding rapamycin to controls had no effect on area and cell 
number, secondly treatment with rapamycin led to further decrease of the area in PRAS40 
(from ~ 65% to 45%) and TSC2 (from ~ 83% to 73%) silenced EBs. These effects might 
be explained as follows: rapamycin preferentially blocks mTORC1 and only later 
mTORC2 (Rosner and Hengstschlager, 2008). Probably EB development is highly 
dependent on rapamycin independent functions of mTORC1 or/and mTORC2. This fits 
well with observations by others as rapamycin did reduce trophoblast outgrowth but was 
unable to impair ICM proliferation (Murakami et al., 2004).Therefore it was suggested 
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that rapamycin might not completely block mTOR activity and that the residual activity 
would be sufficient for embryonic development. Secondly, it was speculated that there 
exists a rapamycin-insensitive function of mTOR (Murakami et al., 2004). Others even 
injected rapamycin into developing embryos and, besides some tissue specific growth 
retardations, the overall embryos developed normally (Hentges et al., 2001). 
Our results and previous studies mentioned above rule out a solely mTORC1 dependent 
pathway. A completely independent role of either mTORC1 or mTORC2 could not be 
proven with the rapamycin experiment. Taking that into account, we knocked down 
mTOR in hAFS cell derived EBs targeting both mTOR complexes. Analyzing p70S6K 
phosphorylation on T389 showed that knocking down mTOR alone did impair 
phosphorylation. Additional knockdown of PRAS40 slightly increased phosphorylation 
again and knockdown of TSC2 and mTOR even led to a greater increase of p70S6K T389 
phosphorylation. Comparing area of single mTOR knockdown with additional 
knockdown of PRAS40 and TSC2 we could show that the decrease in area was almost 
absent in TSC2 (~ 98% compared to 80%) or to a much smaller extent in PRAS40 (~ 
89% compared to 64%) and not significant. Analysis of the cell number reflected the 
results obtained from the area of EBs. Therefore we suggest that PRAS40 and TSC2 
triggered apoptosis in EBs is regulated via mTOR. The here investigated mechanisms is 
dependent on mTORC1 and mTORC2. 
To date it is known that there exist rapamycin sensitive and insensitive mechanisms of 
mTOR signaling. Taking the two main substrates of mTORC1, p70S6K and 4E-BP1, it 
was shown that rapamycin differentially inhibits their phosphorylation and thus activity 
(Choo et al., 2008). p70S6K activity is potently inhibited by the addition of rapamycin 
and starts within minutes of addition (Rosner and Hengstschlager, 2008; Sarbassov et al., 
2006). However, after an initial block within the first 6h the phosphorylation of 4E-BP1 
recovered and authors suggested that 4E-BP1 phosphorylation is rapamycin resistant still 
needing mTORC1 activity (Choo et al., 2008). This makes clear that rapamycin 
differentially regulates mTORC1 substrates (Choo et al., 2008), which could explain our 
finding that rapamycin could not rescue the apoptotic phenotype in PRAS40 and TSC2 
silenced EBs but knockdown of mTOR was. Besides mTORC1, there exists mTORC2 
and in the recent years more was learned about this complex and its regulation. PRAS40 
has only been found to be associated with mTORC1 and not mTORC2 (Oshiro et al., 
2007; Sancak et al., 2007; Thedieck et al., 2007; Vander Haar et al., 2007), yet it was 
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found that rictor knockdown reduced AKT S473 (Rosner et al., 2009b) and PRAS40 
T246 (Thedieck et al., 2007) phosphorylation. This places mTORC2 upstream of 
mTORC1 and one could speculate that the apoptotic phenotype observed in PRAS40 
silenced EBs might be due to deregulated signaling of mTORC2 via PRAS40 and its 
downstream targets. In addition there exist contrary studies on PRAS40 affecting 
mTORC1 signaling. In one study silencing PRAS40 induced phosphorylation of p70S6K 
and 4E-BP1 (Oshiro et al., 2007), whereas in other studies phosphorylation of those two 
mTORC1 substrates was reduced (Fonseca et al., 2007; Nascimento and Ouwens, 2009; 
Vander Haar et al., 2007; Wang et al., 2007; Zhang et al., 2009). Therefore it was 
suggested that PRAS40 might also be playing a role in the assembly and complex 
integrity of mTORC1 (Fonseca et al., 2007; Nascimento and Ouwens, 2009).  
Until 2008 TSC2 has been thought to only regulate mTORC1 but the group of Manning 
presented results providing evidence that TSC2 complex is also binding and regulating 
mTORC2 (Huang et al., 2008). They state that an intact TSC complex is required for 
proper mTORC2 activity and that this regulation is independent of TSC2’s GAP activity 
towards Rheb. 
Taking together the data obtained in this study we could show for the first time that 
PRAS40 and TSC2 are major and essential regulators of early embryonic development. 
Secondly that those two genes are major anti-apoptotic gatekeepers during development 
and thirdly that it is regulated via rapamycin-insensitive functions of mTOR. Further 
investigations have to be done to elucidate the exact mechanism to clarify if those 
apoptotic effects are regulated via rapamycin-insensitive mTORC1 or mTORC2 or both 
complexes. 
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5. LIST OF USED CHEMICALS AND GOODS 
5.1 Chemicals and goods 
30% acryl amid BioRad, Hercules, CA, USA 
96-Well-Plates, U-Form Greiner bio-one, Kremsmünster, Austria 
Agarose Sigma-Aldrich, St.Luis, MO, USA 
Alpha-MEM minimal essential medium Gibco-Invitrogen, Carlsbad, CA, USA 
Albumin bovine serum fraction V (BSA) Sigma-Aldrich, St.Luis, MO, USA 
Ammonium persulfate (APS) BioRad, Hercules, CA, USA 
Aprotinin Sigma-Aldrich, St.Luis, MO, USA 
Benzamidinchloride Sigma-Aldrich, St. Louis, MO, USA 
Bio Rad - protein assay BioRad, Hercules, CA, USA 
Bromophenol blue Merck, Darmstadt, Germany 
Casycup Innovatis-Roche, Bielefeld, Germany 
Casyton Innovatis-Roche, Bielefeld, Germany 
Chang B + C Irvine Scientific, Santa Ana, CA, USA 
CL-Xposeure films Thermo Scientific, Waltham, MA, USA 
DABCO Sigma-Aldrich, St. Louis, MO, USA 
DAPI Sigma-Aldrich, St. Louis, MO, USA 
D-glucose Sigma-Aldrich, St. Louis, MO, USA 
Dithiotreitol (DTT) BioRad, Hercules, CA, USA 
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Dry milk Maresi, Wien, Austria 
DMEM-HG PAA, Linz, Austria 
DMSO Sigma-Aldrich, St. Louis, MO, USA 
EDTA Sigma-Aldrich, St. Louis, MO, USA 
ECL Thermo Scientific, Waltham, MA, USA 
Ethidium Bromide Sigma-Aldrich, St. Louis, MO, USA 
Foetal bovine serum / FCS PAA, Linz, Austria 
GeneRuler 1 kb DNA Ladder Fermentas, Burlington, Canada 
GeneRuler 100 bp DNA Ladder Fermentas, Burlington, Canada 
Glass slides Lab-Tek, Waltham, MA, USA 
Glycerol Merck, Darmstadt, Germany 
Glycin Sigma-Aldrich, St. Louis, MO, USA 
ß-Glycerophosphate Sigma-Aldrich, St. Louis, MO, USA 
HEPES USB, Cleveland, OH, USA 
Hoechst33258 Sigma-Aldrich, St.Luis, MO, USA  
Isopropanol Sigma-Aldrich, St. Louis, MO, USA 
Lauryl sulphate (SDS) Sigma-Aldrich, St. Louis, MO, USA 
Leupeptin Sigma-Aldrich, St. Louis, MO, USA 
L-glutamin PAA, Linz, Austria 
Lipofeactamine 2000 Invitrogen, Carlsbad, CA, USA 
Methanol Sigma-Aldrich, St.Luis, MO, USA 
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Methylcellulose Sigma-Aldrich, St.Luis, MO, USA 
MgCl Merck, Darmstadt, Germany 
2-Mercaptoethanol min 98% Sigma-Aldrich, St.Luis, MO, USA 
Na3VO4 Sigma-Aldrich, St.Luis, MO, USA 
NaCl Sigma-Aldrich, St.Luis, MO, USA 
NaF Sigma-Aldrich, St.Luis, MO, USA 
Needles BD Microlance, Franklin Lakes, NJ, USA 
Nitrocellulose membrane Whatman, Maidstone, UK 
Nonidet P40 subsitute Fluka-Sigma-Aldrich, St.Luis, MO, USA 
OptiMEM Gibco-Invitrogen, Carlsbad, CA, USA 
Paraformaldehyde Sigma-Aldrich, St.Luis, MO, USA 
PBS (1x) PAA, Linz, Austria 
Penicillin Sigma-Aldrich, St.Luis, MO, USA 
Pepsin Sigma-Aldrich, St.Luis, MO, USA 
PMSF Sigma-Aldrich, St.Luis, MO, USA 
Ponceau-S Sigma-Aldrich, St.Luis, MO, USA 
Propidium Iodide Sigma-Aldrich, St.Luis, MO, USA 
Reagent Reservoir Eppendorf, Hamburg, Germany 
RNAiMax Invitrogen, Carlsbad, CA, USA 
RNAse A Sigma-Aldrich, St. Louis, MO, USA 
RPMI 1640 Gibco-Invitrogen, Carlsbad, CA, USA 
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Scalpels Heintel Medizintechnik, Vienna, Austria 
Streptomycin sulphate Sigma-Aldrich, St.Luis, MO, USA 
Syringes BD Plastik, Franklin Lakes, NJ, USA 
TEMED Tetramethyl ethylene diamin BioRad, Hercules, CA, USA 
Trizma base (TRIS) Sigma-Aldrich, St.Luis, MO, USA 
Trisodiumcitrate-2H2O Sigma-Aldrich, St.Luis, MO, USA 
Triton X-100 Sigma-Aldrich, St.Luis, MO, USA 
Trypsin inhibitor Sigma-Aldrich, St.Luis, MO, USA 
Trypsin/EDTA Sigma-Aldrich, St.Luis, MO, USA 
 
 
5.2 siRNAs 
human PRAS40 siRNA   Dharmacon, Lafayette, CO, USA 
human TSC2 siRNA    Dharmacon, Lafayette, CO, USA 
human mTOR siRNA   Dharmacon, Lafayette, CO, USA 
 
5.3 Inhibitors 
Rapamycin     Calbiochem, La Jolla, CA, USA 
Wortmannin     Cell Signaling, Danvers, MA, USA 
LY294002     Calbiochem, La Jolla, CA, USA 
Staurosporine     Sigma-Aldrich, St.Luis, MO, USA 
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5.4 Antibodies 
Primary Antibodies 
Anti-AKT    #9272  Cell Signaling, Danvers, MA, USA 
Anti-AKT S473 (D9E)   #4070  Cell Signaling, Danvers, MA, USA 
Anti-cleaved Caspase3 (5A1E) #9664  Cell Signaling, Danvers, MA, USA 
Anti-laminin    #L9393 Sigma-Aldrich, St.Luis, MO, USA 
Anti-kip1/p27    #610242 BD Bioscience, Franklin Lakes, NJ, USA 
Anti-mTOR    #2972  Cell Signaling, Danvers, MA, USA 
Anti-nestin    #MO15012 Neuromics Antibodies, Edina, MN, USA 
Anti-GAPDH #2275-PC-100 Trevigen Inc., Gaithersburg, MD, USA 
Anti-p70S6K    #9202  Cell Signaling, Danvers, MA, USA 
Anti-p70S6K T389 (108D2)  #9234  Cell Signaling, Danvers, MA, USA 
Anti-PRAS40 (D23C7)  #2691  Cell Signaling, Danvers, MA, USA 
Anti-PRAS40 T246 (C77D7) #2997  Cell Signaling, Danvers, MA, USA 
Anti- S6 (54D2)   #2317  Cell Signaling, Danvers, MA, USA 
Anti- S6 S240/244   #2215  Cell Signaling, Danvers, MA, USA 
Anti-tuberin (C-20) #sc-893 SantaCruz Biotechnology, Santa Cruz,  
   CA, USA 
Anti-topoIIß    #611492 BD Bioscience, Franklin Lakes, NJ, USA 
Anti-WT1 (6F-H2)   #M3561 Dako, Glostrup, Denmark 
Anti-α-Fetoprotein   #AF1369 R&D Systems, Minneapolis, MN, USA 
Anti-α-Tubulin (DM1A)  #CP06  Calbiochem, La Jolla, CA, USA 
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Secondary Antibodies 
Goat anti-Rabbit #A120-101P BethylLaboratories,    
  Montgomery, TX, USA 
Goat anti-Mouse #A90-116P Bethyl Laboratories, Montgomery, TX,  
  USA 
Anti-Mouse-Alexaflour488 #A11029 Invitrogen, Carlsbad, CA, USA 
Anti-Rabbit-Alexaflour546 #A10040 Invitrogen, Carlsbad, CA, USA 
Anti-Mouse-FITC #F0257 Sigma-Aldrich, St.Luis, MO, USA 
Anti-Rabbit-TRITC #T5268 Sigma-Aldrich, St.Luis, MO, USA 
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6. BUFFER AND MEDIA 
6.1 Buffer and reagents 
 Buffer A 20 mM HEPES pH7.9 (USB) 
 0.4 M NaCl (Sigma) 
 25 % glycerol (Merck) 
 1 mM EDTA (Sigma) 
 0.5 mM NaF (Fluka) 
 0.5 mM Na3VO4 (Sigma) 
 0.5 mM DTT (Sigma) 
 dd H2O 
 
 Buffer F1 20mM Tris pH 7,6 
 50mM ß-Mercaptoethanol 
 0,1mM EDTA 
 2mM MgCl2 
 
 50xPIM 100 µg/ml leupeptin (Sigma) 
  100 µg/ml aprotinin (Sigma) 
  15 µg/ml benzamidinchloride (Sigma) 
  500 µg/ml trypsin inhibitor (Sigma) 
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 PMSF 0.1 M PMSF (Sigma) 
  isopropanol (Sigma) 
 
 Buffer B 1.5 M TRIZMA base (Sigma), pH 8.8 
  0.4 % SDS (Sigma) 
 
 Buffer C 0.5 M TRIZMA base (Sigma), pH 8.8 
  0.4 % SDS (Sigma) 
 
 4x loading dye 200 mM Tris, PH6.8 (Sigma) 
 400 mM DTT (Sigma) 
8 % SDS (Sigma) 
0.4 % bromophenol blue (Merck) 
40 % glycerol (Merck) 
 
 Electrophoresis buffer (1 l) 0.25 mol/l TRISMA base (Sigma) 
2 mol/l glycin (Sigma) 
0.035 mol/l SDS (Sigma) 
  ddH2O 
 
 Harlow buffer (1 l) 0.05 mol/l TRISMA base (Sigma) 
0.39 mol/l glycin (Sigma) 
1 g/l SDS (Sigma) 
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  20 % methanol (Sigma) 
  ddH2O 
 
 10x TBS, pH 7.4 1.5 M NaCl (Sigma) 
  0.5 M TRISMA base (Sigma) 
  ddH2O 
  1xTBST 10% 10x TBS, pH 7.4 
  0.1% Triton X-100 (Sigma) 
  ddH2O 
 
 FACS-Stain (PI) 100 ml 117,6 mg Trisodiumcitrate-2H2O (Sigma) 
 25 mg RNAse A (Sigma) 
 5 mg PI (Sigma) 
 100 µl Triton X-100 (Sigma) 
 ddH2O 
 Mounting medium 2,5% DABCO (Sigma) 
 200mM TRIS-HCl, pH8,6 (Sigma) 
 90% glycerol (Merck) 
 ddH2O 
 
 Methylcellulose 7,5g Methylcellulose (autoclaved) 
 500ml basal medium 
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 4% Parafomaldehyde 20g Paraformaldehyde 
 345ml ddH2O 
 5ml 1M NaOH 
 50ml 10xPBS 
 
6.2 Cell culture media 
DMEM-HG medium  DMEM-HG (PAA) 
10% foetal bovine serum (PAA) 
30 mg/l penicillin (Sigma) 
50 mg/l streptomycin sulphate (Sigma) 
 
RPMI 1640 medium   RPMI 1640 (Gibco) 
10% foetal bovine serum (PAA) 
30 mg/l penicillin (Sigma) 
50 mg/l streptomycin sulphate (Sigma) 
 
Standard medium for hAFS cells α-MEM minimal essential medium (Gibco) 
15 % FCS (Hyclone) 
2.5 mM L-glutamine (PAA) 
30 mg/l penicillin (Sigma) 
50 mg/l streptomycin sulphate (Sigma) 
18 % Chang B (Irvine Scientific) 
2 % Chang C (Irvine Scientific) 
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Embryoid body (EB) medium 80% standard medium for hAFS cells 
     20% Methylcellulose 
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8. ABBREVIATIONS 
% percentage 
°C degree Celsius 
µ micro 
µg microgram 
µl microliter 
µm micrometer 
µM micromol 
µm² square micrometer 
4E-BP1 eukaryotic initiation factor 4E (eIF4E) binding protein 1
AF cells amniotic fluid cells 
AFS cells amniotic fluid stem cells 
AKT v-Akt murine thymoma viral oncogene homolog  
AMPK AMP kinase 
ATCC American Type Culture Collection 
ATP adenosine-5'-triphosphate 
BAD Bcl-2-associated death promoter 
BSA bovine serum albumin 
CASY brand name; Casy cell Counter 
CD105 endoglin 
CD117 c-kit, receptor for stem cell factor 
CD34 hematopoietic progenitor cell antigen CD34 
CD44 hermes antigen 
CD45 protein-tyrosine phosphatase, receptor type C 
c-kit see CD117 
c-myc V-myc myelocytomatosis viral oncogene homolog 
DABCO 1,4-Diazabicyclo(2,2,2)octane 
DAPI 4',6-diamidin-2'-phenylindol- dihydrochlorid  
DMEM Dulbecco's Modified Eagle Medium  
DMEM-HG Dulbecco's Modified Eagle Medium, high glucose 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
DTT dithiothreitol 
e.g. exempli gratia (for example) 
EB embryoid body 
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ECL enhanced chemilumescence 
ECM extracellular matrix 
EDTA ethylene 
eIF4E eukaryotic translation initiation factor 4E 
ERK extracellular-signal-regulated kinase 
ES cells embryonic stem cells 
FACS fluorescence activated cell sorting 
FCS fetal calf serum 
FKBP12 FK506-binding protein 12 
FOXO forkhead box protein 
FRB domain FKBP12-rapamycin binding domain 
FSC forward scatter 
g gram 
GAP GTPase activating protein 
Gβl/mLST8 G-protein β-subunit like protein/mammalian LST8 
h human 
h hour 
H2O Aqua dest. 
hAFS cell human amniotic fluid stem cell 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HIF hypoxia inducible factor 
IGF-1 insulin-like growth factor 1 
IgG immunoglobulin G 
iPS cell induced pluripotent stem cell 
IRS insulin receptor substrate 
kDa kilodalton 
l litre 
LAM lymphangioleiomyomatosis 
LKB1 serine/threonine kinase 11 
M Mol 
MAPK mitogen-activated protein kinase 
MC Methylcellulose 
mg milligram 
ml millilitre 
mM millimol 
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mRNA messenger RNA 
mSin1 mammalian stress-activated protein kinase interacting protein 1 
mTOR mammalian target of rapamycin 
mTORC 1 mammalian target of rapamycin complex 1 
mTORC 2 mammalian target of rapamycin complex 2 
Oct-4 octamer-binding transcription factor 4 
p70 S6K ribosomal protein S6-kinase, 70 kDa 
PBS phosphate buffered saline 
PDK1 3-phosphoinositide dependent protein kinase-1 
PFA paraformaldehyde 
pH potentiometric hydrogen ion concentration  
PI propidium iodide 
PI3K phosphatidylinositol 3-kinase 
PIKK phosphoinositide 3-kinase related kinase 
PIM protease inhibitor mix 
PIP2 phosphatidylinositol 4,5-biphosphate 
PIP3 phosphatidylinositol (3,4,5)-triphosphate 
PMSF phenylmethylsulfonyl fluoride  
PRAS40 proline-rich AKT substrate of 40 kDa 
PRR5/protor proline-rich protein 5/protein observed with rictor 
PTEN phosphatase and tensin homolog 
Rag Ras-related GTP-binding protein 
raptor regulatory associated protein of mTOR  
Ras rat sarcoma 
Rheb ras-homologe enriched in brain 
rictor rapamycin insensitive companion of mTOR  
RNA ribonucleic acid 
rpm rotations per minute 
RPMI medium Roswell Park Memorial Institute medium 
RSK1 90kDa ribosomal S6 kinase1 
S serine 
S6 ribosomal protein S6  
S6K1 ribosomal protein S6 kinase 1 
S6K2 ribosomal protein S6 kinase 2 
SD standard deviation 
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SDS sodium dodecyl sulfate 
siRNA small interfering RNA 
Sox2 SRY (sex determining region Y)-box 2 
STK11/LKB1 Serine/threonine kinase 11 
T threonine 
TBS tris buffered saline 
TBS-T tris buffer saline + Triton X-100 
TEMED N, N, N', N'-tetramethylethylenediamine  
TOS motif TOR signalling motif 
TSC tuberous sclerosis complex 
TSC1 tuberous sclerosis complex 1 / hamartin 
TSC2 tuberous sclerosis complex 2 / tuberin 
UK United Kingdom 
USA United States of America 
UTR untranslated region 
v/v volume/volume 
VEGF vascular endothelial growth factor 
αFP alpha fetoprotein 
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